<?xml version='1.0' encoding='iso-8859-1'?>
<PASBIO>
    <framesest>
        <predicate lemma="block">
            <roleset id="block.01" name="" wordnet="3">
                <roles>
                    <role n="0" descr="causer agent&#10;" />
                    <role n="1" descr="theme (process or entity being stopped)&#10;" />
                </roles>
                <example src="EGRAM" no="0">
					<text>Descending kinase seems to be essential for agron-mediated signaling, since arg-induced AChR grouping and phosphorylation could be blocked by staurosporin without inhibiting musK phosphorylation (Wallace, 1994; Fuhrer et al., 1997).</text>
					<arg n="0">staurosporin</arg>
					<arg n="1">arg-induced AChR grouping and phosphorylation</arg>
				</example>
				<example src="EGRAM" no="0">
					<text>The descending flow kinase seemed to be essential for agrine-mediated signaling, since agrine-induced AChR and phosphorylation can be blocked by staurosporin without inhibiting musK phosphorylation (Wallace, 1994; Fuhrer et al., 1997).</text>
					<arg n="0">staurosporin</arg>
					<arg n="1">agrine-induced AChR and phosphorylation</arg>
				</example>
				<example src="EGRAM" no="1">
					<text>Descending kinase seemed to be essential for agron-mediated signaling, since arg-induced AChR grouping and phosphorylation was able to be blocked by staurosporin without inhibiting musK phosphorylation (Wallace, 1994; Fuhrer et al., 1997).</text>
					<arg n="0">staurosporin</arg>
					<arg n="1">arg-induced AChR grouping and phosphorylation</arg>
				</example>
				<example src="EGRAM" no="1">
					<text>The descending flow kinase seemed to be essential for agrine-mediated signaling, since agrin-induced AChR clustering and phosphorylation was able to be blocked by staurosporin without inhibiting musK phosphorylation (Wallace, 1994; Fuhrer et al., 1997).</text>
					<arg n="0">staurosporin</arg>
					<arg n="1">agrin-induced AChR clustering and phosphorylation</arg>
				</example>
				<example src="EGRAM" no="2">
					<text>A descending kinase seemed essential for agron-mediated signaling, as it was believed that argon-induced AChR grouping and phosphorylation was blocked by staurosporin without inhibiting MuSK phosphorylation (Wallace, 1994; Fuhrer et al., 1997).</text>
					<arg n="0">staurosporin</arg>
					<arg n="1">argon-induced AChR grouping and phosphorylation</arg>
				</example>
				<example src="EGRAM" no="2">
					<text>The descending flow kinase seemed to be essential for agrine-mediated signaling, since agrine-induced AChR and phosphorylation was considered to be blocked by sporin without inhibiting musK phosphorylation (Wallace, 1994; Fuhrer et al., 1997).</text>
					<arg n="0">sporin</arg>
					<arg n="1">agrine-induced AChR and phosphorylation</arg>
				</example>
				<example src="EGRAM" no="3">
					<text>The downward flow of kinase seemed essential for the agron-mediated signaling, since AChR and arrhine-induced phosphorylation would be blocked by staurosporin without inhibiting phosphorylation of musK (Wallace, 1994; Fuhrer et al., 1997).</text>
					<arg n="0">staurosporin</arg>
					<arg n="1">AChR and arrhine-induced phosphorylation</arg>
				</example>
				<example src="EGRAM" no="3">
					<text>The descending flow kinase seemed to be essential for agrine-mediated signaling, since agrine-induced AChR and phosphorylation would be blocked by staurosporin without inhibiting musK phosphorylation (Wallace, 1994; Fuhrer et al., 1997).</text>
					<arg n="0">staurosporin</arg>
					<arg n="1">agrine-induced AChR and phosphorylation</arg>
				</example>
				<example src="EGRAM" no="4">
					<text>Descending kinase seemed to be essential for pesticide-mediated signaling, since sporin blocked agrona-induced AChR grouping and phosphorylation without inhibiting musK phosphorylation (Wallace, 1994; Fuhrer et al., 1997).</text>
					<arg n="0">sporin</arg>
					<arg n="1">agrona-induced AChR grouping and phosphorylation</arg>
				</example>
				<example src="EGRAM" no="4">
					<text>The descending flow kinase seemed to be essential for agrine-mediated signaling, since staurosporin blocked agrin-induced AChR clustering and phosphorylation without inhibiting musK phosphorylation (Wallace, 1994; Fuhrer et al., 1997).</text>
					<arg n="0">staurosporin</arg>
					<arg n="1">agrin-induced AChR clustering and phosphorylation</arg>
				</example>
				<example src="EGRAM" no="5">
					<text>Descending kinase seemed to be essential for agroane-mediated signaling, since staurosporin could block agrena-induced AChR grouping and phosphorylation without inhibiting musK phosphorylation (Wallace, 1994; Fuhrer et al., 1997).</text>
					<arg n="0">staurosporin</arg>
					<arg n="1">agrena-induced AChR grouping and phosphorylation</arg>
				</example>
				<example src="EGRAM" no="5">
					<text>The descending flow kinase seemed to be essential for agrine-mediated signaling, since staurosporin could block agrine-induced AChR and phosphorylation without inhibiting musK phosphorylation (Wallace, 1994; Fuhrer et al., 1997).</text>
					<arg n="0">staurosporin</arg>
					<arg n="1">agrine-induced AChR and phosphorylation</arg>
				</example>
				<example src="EGRAM" no="6">
					<text>A descending kinase seemed essential for agrofood mediated signaling, since staurosporin had blocked agronin-induced AChR grouping and phosphorylation without inhibiting MuSK phosphorylation (Wallace, 1994; Fuhrer et al., 1997).</text>
					<arg n="0">staurosporin</arg>
					<arg n="1">agronin-induced AChR grouping and phosphorylation</arg>
				</example>
				<example src="EGRAM" no="6">
					<text>The descending flow kinase seemed to be essential for agrine-mediated signaling, since staurosporin blocked agrine-induced AChR and phosphorylation without inhibiting musK phosphorylation (Wallace, 1994; Fuhrer et al., 1997).</text>
					<arg n="0">staurosporin</arg>
					<arg n="1">agrine-induced AChR and phosphorylation</arg>
				</example>
				<example src="EGRAM" no="7">
					<text>Descending kinase seemed to be essential for agroane-mediated signaling, since staurosporin could block agrena-induced AChR grouping and phosphorylation without inhibiting musK phosphorylation (Wallace, 1994; Fuhrer et al., 1997).</text>
					<arg n="0">staurosporin</arg>
					<arg n="1">agrena-induced AChR grouping and phosphorylation</arg>
				</example>
				<example src="EGRAM" no="7">
					<text>The descending flow kinase seemed to be essential for agrine-mediated signaling, since staurosporin may block aggregation and phosphorylation of AChR induced by agrine without inhibiting musK phosphorylation (Wallace, 1994; Fuhrer et al., 1997).</text>
					<arg n="0">staurosporin</arg>
					<arg n="1">aggregation and phosphorylation of AChR induced by agrine</arg>
				</example>
				<example src="EGRAM" no="8">
					<text>The downward flow of kinase seemed essential for the agron-mediated signaling, since staurosporin could have blocked AChR and arrhine-induced phosphorylation without inhibiting musK phosphorylation (Wallace, 1994; Fuhrer et al., 1997).</text>
					<arg n="0">staurosporin</arg>
					<arg n="1">AChR and arrhine-induced phosphorylation</arg>
				</example>
				<example src="EGRAM" no="8">
					<text>The descending flow kinase seemed to be essential for agrine-mediated signaling, since staurosporin may have blocked agrine-induced AChR and phosphorylation without inhibiting musK phosphorylation (Wallace, 1994; Fuhrer et al., 1997).</text>
					<arg n="0">staurosporin</arg>
					<arg n="1">agrine-induced AChR and phosphorylation</arg>
				</example>
				<example src="EGRAM" no="9">
					<text>Descending kinase seemed to be essential for agroane-mediated signaling, since staurosporin was able to block agrona-induced AChR grouping and phosphorylation without inhibiting musK phosphorylation (Wallace, 1994; Fuhrer et al., 1997).</text>
					<arg n="0">staurosporin</arg>
					<arg n="1">agrona-induced AChR grouping and phosphorylation</arg>
				</example>
				<example src="EGRAM" no="9">
					<text>The descending flow kinase seemed to be essential for agrine-mediated signaling, since staurosporin was able to block aggregation and phosphorylation of AChR induced by agrine without inhibiting musK phosphorylation (Wallace, 1994; Fuhrer et al., 1997).</text>
					<arg n="0">staurosporin</arg>
					<arg n="1">aggregation and phosphorylation of AChR induced by agrine</arg>
				</example>
				<example src="EGRAM" no="10">
					<text>Descending kinase seemed essential for pesticide-mediated signaling, because it is believed that staurosporin blocks aggregation AChR induced by agrone and phosphorylation without block phosphorylation musK (Wallace, 1994; Fuhrer et al., 1997).</text>
					<arg n="0">staurosporin</arg>
					<arg n="1">aggregation AChR induced by agrone and phosphorylation</arg>
				</example>
				<example src="EGRAM" no="10">
					<text>The descending flow kinase seemed to be essential for agrine-mediated signaling, since staurosporin was considered to inhibit muscle phosphorylation (Wallace, 1994; Fuhrer et al., 1997) to block agrine-induced AChR and phosphorylation without inhibiting muscle phosphorylation (Wallace, 1994; Fuhrer et al., 1997</text>
					<arg n="0">staurosporin</arg>
					<arg n="1">agrine-induced AChR and phosphorylation</arg>
				</example>
				<example src="EGRAM" no="11">
					<text>The descending kinase seemed essential for pesticide-mediated signaling, because it is believed that staurosporin has blocked phosphorylation and AChR cluster induced by agronin without inhibiting musK phosphorylation (Wallace, 1994; Fuhrer et al., 1997).</text>
					<arg n="0">staurosporin</arg>
					<arg n="1">phosphorylation and AChR cluster induced by agronin</arg>
				</example>
				<example src="EGRAM" no="11">
					<text>The descending flow kinase seemed to be essential for agrine-mediated signaling, since staurosporin was blocked to be an inhibitor of muscle phosphorylation (Wallace, 1994; Fuhrer et al., 1997) and that the descending flow kinase was blocked essential for agrine-mediated signaling, since staurosporin was blocked to be an inhibitor</text>
					<arg n="0">staurosporin</arg>
				</example>
				<example src="EGRAM" no="12">
					<text>Descending kinase seemed to be essential for pesticide-mediated signaling, as staurosporin was blocking agrenin-induced AChR grouping and phosphorylation without inhibiting musK phosphorylation (Wallace, 1994; Fuhrer et al., 1997).</text>
					<arg n="0">staurosporin</arg>
					<arg n="1">agrenin-induced AChR grouping and phosphorylation</arg>
				</example>
				<example src="EGRAM" no="12">
					<text>The descending flow kinase seemed to be essential for agrine-mediated signaling, since staurosporin was blocking agrine-induced AChR and phosphorylation without inhibiting musK phosphorylation (Wallace, 1994; Fuhrer et al., 1997).</text>
					<arg n="0">staurosporin</arg>
					<arg n="1">agrine-induced AChR and phosphorylation</arg>
				</example>
				<example src="EGRAM" no="13">
					<text>Descending kinase seems to be essential for agron-mediated signaling, due to the ability of staurosporin to block agrinin-induced AChR grouping and phosphorylation without inhibiting musK phosphorylation (Wallace, 1994; Fuhrer et al., 1997).</text>
					<arg n="0">staurosporin</arg>
					<arg n="1">agrinin-induced AChR grouping and phosphorylation</arg>
				</example>
				<example src="EGRAM" no="13">
					<text>Descending flow kinase seems to be essential for agrine-mediated signaling, due to the ability of staurosporin to block agrine-induced AChR and phosphorylation without inhibiting musK phosphorylation (Wallace, 1994; Fuhrer et al., 1997).</text>
					<arg n="0">staurosporin</arg>
					<arg n="1">agrine-induced AChR and phosphorylation</arg>
				</example>
				<example src="EGRAM" no="14">
					<text>A descending kinase appears to be essential for agron mediated signaling due to staurosporin which blocks agrona-induced AChR grouping and phosphorylation without blocking MuSK phosphorylation (Wallace, 1994; Fuhrer et al., 1997).</text>
					<arg n="0">staurosporin</arg>
					<arg n="1">agrona-induced AChR grouping and phosphorylation</arg>
				</example>
				<example src="EGRAM" no="14">
					<text>Descending kinase seems to be essential for agron-mediated signaling due to staurosporin that blocks agrona-induced AChR grouping and phosphorylation without blocking musK phosphorylation (Wallace, 1994; Fuhrer et al., 1997).</text>
					<arg n="0">staurosporin</arg>
					<arg n="1">agrona-induced AChR grouping and phosphorylation</arg>
				</example>
				<example src="EGRAM" no="15">
					<text>Descending flow kinase appears essential for agron-mediated signaling, since agrin-induced AChR grouping and phosphorylation is able to be blocked by staurosporin without inhibiting phosphorylation of musK (Wallace, 1994; Fuhrer et al., 1997).</text>
					<arg n="0">staurosporin</arg>
					<arg n="1">agrin-induced AChR grouping and phosphorylation</arg>
				</example>
				<example src="EGRAM" no="15">
					<text>Descending flow kinase seems to be essential for agrine-mediated signaling, since agrin-induced AChR clustering and phosphorylation is able to be blocked by staurosporin without inhibiting musK phosphorylation (Wallace, 1994; Fuhrer et al., 1997).</text>
					<arg n="0">staurosporin</arg>
					<arg n="1">agrin-induced AChR clustering and phosphorylation</arg>
				</example>
				<example src="EGRAM" no="16">
					<text>A descending kinase appears essential for agron-mediated signaling, since argon-induced AChR grouping and phosphorylation is believed to be blocked by A0 (staurosporin) without inhibiting MuSK phosphorylation (Wallace, 1994; Fuhrer et al., 1997) (argon-induced AChR grouping and phosphorylation is believed to be blocked by staurosporin without inhibiting MuSK phosphorylation (Wallace, 1994; Fuhrer et al., 1997).</text>
					<arg n="0">staurosporin</arg>
					<arg n="1">argon-induced AChR grouping and phosphorylation is believed to be blocked by A0 (staurosporin) without inhibiting MuSK phosphorylation (Wallace, 1994; Fuhrer et al., 1997)</arg>
				</example>
				<example src="EGRAM" no="16">
					<text>Descending kinase seems to be essential for agron-mediated signaling, since argon-induced AChR grouping and phosphorylation is considered to be blocked by staurosporin without inhibiting musK phosphorylation (Wallace, 1994; Fuhrer et al., 1997).</text>
					<arg n="0">staurosporin</arg>
					<arg n="1">argon-induced AChR grouping and phosphorylation</arg>
				</example>
				<example src="EGRAM" no="17">
					<text>Descending flow kinase appears essential for agron-mediated signaling, since AChR and arrhine-induced phosphorylation is blocked by staurosporin without inhibiting phosphorylation of musK (Wallace, 1994; Fuhrer et al., 1997).</text>
					<arg n="0">staurosporin</arg>
					<arg n="1">AChR and arrhine-induced phosphorylation</arg>
				</example>
				<example src="EGRAM" no="17">
					<text>Descending flow kinase seems to be essential for agrine-mediated signaling, since agrine-induced AChR and phosphorylation is blocked by staurosporin without inhibiting musK phosphorylation (Wallace, 1994; Fuhrer et al., 1997).</text>
					<arg n="0">staurosporin</arg>
					<arg n="1">agrine-induced AChR and phosphorylation</arg>
				</example>
				<example src="EGRAM" no="18">
					<text>Descending flow kinase seems to be essential for agrine-mediated signaling, since agrine-induced AChR and phosphorylation can be blocked by staurosporin without inhibiting musK phosphorylation (Wallace, 1994; Fuhrer et al., 1997).</text>
					<arg n="0">staurosporin</arg>
					<arg n="1">agrine-induced AChR and phosphorylation</arg>
				</example>
				<example src="EGRAM" no="18">
					<text>A descending kinase appears to be essential for agron-mediated signaling, since argon-induced AChR grouping and phosphorylation can be blocked by staurosporin without inhibiting MuSK phosphorylation (Wallace, 1994; Fuhrer et al., 1997).</text>
					<arg n="0">staurosporin</arg>
					<arg n="1">argon-induced AChR grouping and phosphorylation</arg>
				</example>
				<example src="EGRAM" no="19">
					<text>Descending-flow kinase appears essential for agron-mediated signaling, since AChR and arrhine-induced phosphorylation was blocked by sporin without inhibiting phosphorylation of musK (Wallace, 1994; Fuhrer et al., 1997).</text>
					<arg n="0">sporin</arg>
					<arg n="1">AChR and arrhine-induced phosphorylation</arg>
				</example>
				<example src="EGRAM" no="19">
					<text>Descending flow kinase seems to be essential for agrine-mediated signaling, since agrine-induced AChR and phosphorylation was blocked by sporin without inhibiting musK phosphorylation (Wallace, 1994; Fuhrer et al., 1997).</text>
					<arg n="0">sporin</arg>
					<arg n="1">agrine-induced AChR and phosphorylation</arg>
				</example>
				<example src="EGRAM" no="20">
					<text>Descending-flow kinase appears essential for agron-mediated signaling, since AChR and arrhine-induced phosphorylation can be blocked by staurosporin without inhibiting phosphorylation of musK (Wallace, 1994; Fuhrer et al., 1997).</text>
					<arg n="0">staurosporin</arg>
					<arg n="1">AChR and arrhine-induced phosphorylation</arg>
				</example>
				<example src="EGRAM" no="20">
					<text>Descending flow kinase seems to be essential for agrine-mediated signaling, since agrine-induced AChR and phosphorylation can be blocked by staurosporin without inhibiting musK phosphorylation (Wallace, 1994; Fuhrer et al., 1997).</text>
					<arg n="0">staurosporin</arg>
					<arg n="1">agrine-induced AChR and phosphorylation</arg>
				</example>
				<example src="EGRAM" no="21">
					<text>Descending kinase seems to be essential for agron-mediated signaling, since aggregation and phosphorylation AChR induced in agro was blocked by sporin without inhibiting musK phosphorylation (Wallace, 1994; Fuhrer et al., 1997).</text>
					<arg n="0">sporin</arg>
					<arg n="1">aggregation and phosphorylation AChR induced in agro</arg>
				</example>
				<example src="EGRAM" no="21">
					<text>A descending kinase appears to be essential for agron-mediated signaling, since grouping and phosphorylation AChR induced in agro were blocked by staurosporin without inhibiting MuSK phosphorylation (Wallace, 1994; Fuhrer et al., 1997).</text>
					<arg n="0">staurosporin</arg>
					<arg n="1">grouping and phosphorylation AChR induced in agro</arg>
				</example>
				<example src="EGRAM" no="22">
					<text>Descending flow kinase seems to be essential for agrine-mediated signaling, since agrine-induced AChR and phosphorylation will be blocked by staurosporin without inhibiting musK phosphorylation (Wallace, 1994; Fuhrer et al., 1997).</text>
					<arg n="0">staurosporin</arg>
					<arg n="1">agrine-induced AChR and phosphorylation</arg>
				</example>
				<example src="EGRAM" no="22">
					<text>A descending kinase appears to be essential for agron-mediated signaling, since argon-induced AChR grouping and phosphorylation will be blocked by staurosporin without inhibiting MuSK phosphorylation (Wallace, 1994; Fuhrer et al., 1997).</text>
					<arg n="0">staurosporin</arg>
					<arg n="1">argon-induced AChR grouping and phosphorylation</arg>
				</example>
				<example src="EGRAM" no="23">
					<text>Descending flow kinase appears essential for agron-mediated signaling, since staurosporin can block AChR and arrhine-induced phosphorylation without inhibiting musK phosphorylation (Wallace, 1994; Fuhrer et al., 1997).</text>
					<arg n="0">staurosporin</arg>
					<arg n="1">AChR and arrhine-induced phosphorylation</arg>
				</example>
				<example src="EGRAM" no="23">
					<text>Descending flow kinase seems to be essential for agrine-mediated signaling, since staurosporin may block agrine-induced AChR and phosphorylation without inhibiting musK phosphorylation (Wallace, 1994; Fuhrer et al., 1997).</text>
					<arg n="0">staurosporin</arg>
					<arg n="1">agrine-induced AChR and phosphorylation</arg>
				</example>
				<example src="EGRAM" no="24">
					<text>Descending-flow kinase appears essential for agron-mediated signaling, as sturosporin blocked aggregation and phosphorylation of AChR induced by aggron without inhibiting phosphorylation of musK (Wallace, 1994; Fuhrer et al., 1997).</text>
					<arg n="0">sturosporin</arg>
					<arg n="1">aggregation and phosphorylation of AChR induced by aggron</arg>
				</example>
				<example src="EGRAM" no="24">
					<text>Descending flow kinase seems to be essential for agrine-mediated signaling, since staurosporin blocked aggregation and phosphorylation of AChR induced by agrine without inhibiting musK phosphorylation (Wallace, 1994; Fuhrer et al., 1997).</text>
					<arg n="0">staurosporin</arg>
					<arg n="1">aggregation and phosphorylation of AChR induced by agrine</arg>
				</example>
				<example src="EGRAM" no="25">
					<text>Descending flow kinase appears essential for agronic-mediated signaling, since staurosporin is able to block aggregation and phosphorylation of AChR induced by aggron without inhibiting phosphorylation of musK (Wallace, 1994; Fuhrer et al., 1997).</text>
					<arg n="0">staurosporin</arg>
					<arg n="1">aggregation and phosphorylation of AChR induced by aggron</arg>
				</example>
				<example src="EGRAM" no="25">
					<text>Descending flow kinase seems to be essential for agrine-mediated signaling, since staurosporin is able to block aggregation and phosphorylation of AChR induced by agrine without inhibiting musK phosphorylation (Wallace, 1994; Fuhrer et al., 1997).</text>
					<arg n="0">staurosporin</arg>
					<arg n="1">aggregation and phosphorylation of AChR induced by agrine</arg>
				</example>
				<example src="EGRAM" no="26">
					<text>Descending flow kinase appears to be essential for agron-mediated signaling, as staurosporin is thought to block aggregation and phosphorylation of AChR induced by aggron without inhibiting phosphorylation of musK (Wallace, 1994; Fuhrer et al., 1997).</text>
					<arg n="0">staurosporin</arg>
					<arg n="1">aggregation and phosphorylation of AChR induced by aggron</arg>
				</example>
				<example src="EGRAM" no="26">
					<text>Descending flow kinase seems to be essential for agrine-mediated signaling, since staurosporin is believed to block aggregation and phosphorylation of AChR induced by agrine without inhibiting musK phosphorylation (Wallace, 1994; Fuhrer et al., 1997).</text>
					<arg n="0">staurosporin</arg>
					<arg n="1">aggregation and phosphorylation of AChR induced by agrine</arg>
				</example>
				<example src="EGRAM" no="27">
					<text>Descending-flow kinase appears essential for agron-mediated signaling, as sturosporin is thought to have blocked aggregation and phosphorylation of AChR induced by aggron without inhibiting phosphorylation of musK (Wallace, 1994; Fuhrer et al., 1997).</text>
					<arg n="0">sturosporin</arg>
					<arg n="1">aggregation and phosphorylation of AChR induced by aggron</arg>
				</example>
				<example src="EGRAM" no="27">
					<text>Descending flow kinase seems to be essential for agrine-mediated signaling, since it is believed that staurosporin has blocked aggregation and phosphorylation of AChR induced by agrine without inhibiting musK phosphorylation (Wallace, 1994; Fuhrer et al., 1997).</text>
					<arg n="0">staurosporin</arg>
					<arg n="1">aggregation and phosphorylation of AChR induced by agrine</arg>
				</example>
				<example src="EGRAM" no="28">
					<text>Descending flow kinase appears essential for agron-mediated signaling, since staurosporin is blocking aggregation and phosphorylation of AChR induced by aggron without inhibiting phosphorylation of musK (Wallace, 1994; Fuhrer et al., 1997).</text>
					<arg n="0">staurosporin</arg>
					<arg n="1">aggregation and phosphorylation of AChR induced by aggron</arg>
				</example>
				<example src="EGRAM" no="28">
					<text>Descending flow kinase seems to be essential for agrine-mediated signaling, since staurosporin is blocking aggregation and phosphorylation of AChR induced by agrine without inhibiting musK phosphorylation (Wallace, 1994; Fuhrer et al., 1997).</text>
					<arg n="0">staurosporin</arg>
					<arg n="1">aggregation and phosphorylation of AChR induced by agrine</arg>
				</example>
				<example src="EGRAM" no="29">
					<text>A descending kinase appears to be essential for agroana mediated signaling, since staurosporin can block agrona-induced AChR grouping and phosphorylation without inhibiting MuSK phosphorylation (Wallace, 1994; Fuhrer et al., 1997).</text>
					<arg n="0">staurosporin</arg>
					<arg n="1">agrona-induced AChR grouping and phosphorylation</arg>
				</example>
				<example src="EGRAM" no="29">
					<text>Descending flow kinase seems to be essential for agrine-mediated signaling, since staurosporin may block aggregation and phosphorylation of AChR induced by agrine without inhibiting musK phosphorylation (Wallace, 1994; Fuhrer et al., 1997).</text>
					<arg n="0">staurosporin</arg>
					<arg n="1">aggregation and phosphorylation of AChR induced by agrine</arg>
				</example>
				<example src="EGRAM" no="30">
					<text>Descending kinase seems essential for pesticide-mediated signaling, since staurosporin may have blocked aggregation AChR induced by agronin and phosphorylation without inhibiting musK phosphorylation (Wallace, 1994; Fuhrer et al., 1997).</text>
					<arg n="0">staurosporin</arg>
					<arg n="1">aggregation AChR induced by agronin and phosphorylation</arg>
				</example>
				<example src="EGRAM" no="30">
					<text>Descending flow kinase seems to be essential for agrine-mediated signaling, since staurosporin may have blocked agrine-induced AChR and phosphorylation without inhibiting musK phosphorylation (Wallace, 1994; Fuhrer et al., 1997).</text>
					<arg n="0">staurosporin</arg>
					<arg n="1">agrine-induced AChR and phosphorylation</arg>
				</example>
				<example src="EGRAM" no="31">
					<text>alanine blocked the action of a postulate suppressant.</text>
					<arg n="0">alanine</arg>
					<arg n="1">the action of a postulate suppressant</arg>
				</example>
				<example src="EGRAM" no="31">
					<text>alanine blocked the action of a postulated repressor.</text>
					<arg n="0">alanine</arg>
					<arg n="1">the action of a postulated repressor</arg>
				</example>
				<example src="EGRAM" no="32">
					<text>blocksablockslblocksablocksnblocksiblocksnblockseblocks blocksbblockslblocksoblockscblockskblockssblocks blockstblockshblockseblocks blocksablockscblockstblocksiblocksoblocksnblocks blocksoblocksfblocks blocksablocks blockspblocksoblockssblockstblocksublockslblocksablockstblockseblocks blocksrblockseblockspblocksrblockseblockssblockssblocksoblocksrblocks.blocks</text>
					<arg n="0">alanine</arg>
					<arg n="1">the action of a postulate repressor</arg>
				</example>
				<example src="EGRAM" no="32">
					<text>blocksablockslblocksablocksnblocksiblocksnblockseblocks blocksbblockslblocksoblockscblockskblockssblocks blockstblockshblockseblocks blocksablockscblockstblocksiblocksoblocksnblocks blocksoblocksfblocks blocksablocks blockspblocksoblockssblockstblocksublockslblocksablockstblockseblocksdblocks blocksrblockseblockspblocksrblockseblockssblockssblocksoblocksrblocks.blocks</text>
					<arg n="0">alanine</arg>
					<arg n="1">the action of a postulated repressor</arg>
				</example>
				<example src="EGRAM" no="33">
					<text>Alanine can block the action of a postulate repressor.</text>
					<arg n="0">Alanine</arg>
					<arg n="1">the action of a postulate repressor</arg>
				</example>
				<example src="EGRAM" no="33">
					<text>alanine can block the action of a postulate repressor.</text>
					<arg n="0">alanine</arg>
					<arg n="1">the action of a postulate repressor</arg>
				</example>
				<example src="EGRAM" no="34">
					<text>alanine may have blocked the action of a postulate repressor.</text>
					<arg n="0">alanine</arg>
					<arg n="1">the action of a postulate repressor</arg>
				</example>
				<example src="EGRAM" no="34">
					<text>alanine may have blocked the action of a postulate repressor.</text>
					<arg n="0">alanine</arg>
					<arg n="1">the action of a postulate repressor</arg>
				</example>
				<example src="EGRAM" no="35">
					<text>alanine can block the action of a postulate repressor.</text>
					<arg n="0">alanine</arg>
					<arg n="1">the action of a postulate repressor</arg>
				</example>
				<example src="EGRAM" no="35">
					<text>Alanine could block the action of a postulate repressor.</text>
					<arg n="0">Alanine</arg>
					<arg n="1">the action of a postulate repressor</arg>
				</example>
				<example src="EGRAM" no="36">
					<text>alanine may have blocked the action of a postulate repressor.</text>
					<arg n="0">alanine</arg>
					<arg n="1">the action of a postulate repressor</arg>
				</example>
				<example src="EGRAM" no="36">
					<text>alanine may have blocked the action of a postulate repressor.</text>
					<arg n="0">alanine</arg>
					<arg n="1">the action of a postulate repressor</arg>
				</example>
				<example src="EGRAM" no="37">
					<text>alanine blocked the action of a postulated repressor.</text>
					<arg n="0">alanine</arg>
					<arg n="1">the action of a postulated repressor</arg>
				</example>
				<example src="EGRAM" no="37">
					<text>Alanine has blocked the action of a postulate repressor.</text>
					<arg n="0">Alanine</arg>
					<arg n="1">the action of a postulate repressor</arg>
				</example>
				<example src="EGRAM" no="38">
					<text>alanine is able to block the action of a postulate repressor.</text>
					<arg n="0">alanine</arg>
					<arg n="1">the action of a postulate repressor</arg>
				</example>
				<example src="EGRAM" no="38">
					<text>alanine is able to block the action of a postulate repressor.</text>
					<arg n="0">alanine</arg>
					<arg n="1">the action of a postulate repressor</arg>
				</example>
				<example src="EGRAM" no="39">
					<text>alanine is thought to block the action of a postulate repressor.</text>
					<arg n="0">alanine</arg>
					<arg n="1">the action of a postulate repressor</arg>
				</example>
				<example src="EGRAM" no="39">
					<text>alanine is thought to block the action of a postulate repressor.</text>
					<arg n="0">alanine</arg>
					<arg n="1">the action of a postulate repressor</arg>
				</example>
				<example src="EGRAM" no="40">
					<text>alanine may block the action of a postulate repressor.</text>
					<arg n="0">alanine</arg>
					<arg n="1">the action of a postulate repressor</arg>
				</example>
				<example src="EGRAM" no="40">
					<text>alanine may block the action of a postulated repressor.</text>
					<arg n="0">alanine</arg>
					<arg n="1">the action of a postulated repressor</arg>
				</example>
				<example src="EGRAM" no="41">
					<text>alanine may have blocked the action of a postulate repressor.</text>
					<arg n="0">alanine</arg>
					<arg n="1">the action of a postulate repressor</arg>
				</example>
				<example src="EGRAM" no="41">
					<text>alanine may have blocked the action of a postulate repressor.</text>
					<arg n="0">alanine</arg>
					<arg n="1">the action of a postulate repressor</arg>
				</example>
				<example src="EGRAM" no="42">
					<text>alanine may block the action of a postulate repressor.</text>
					<arg n="0">alanine</arg>
					<arg n="1">the action of a postulate repressor</arg>
				</example>
				<example src="EGRAM" no="42">
					<text>alanine may block the action of a postulated repressor.</text>
					<arg n="0">alanine</arg>
					<arg n="1">the action of a postulated repressor</arg>
				</example>
				<example src="EGRAM" no="43">
					<text>alanine may have blocked the action of a postulate repressor.</text>
					<arg n="0">alanine</arg>
					<arg n="1">the action of a postulate repressor</arg>
				</example>
				<example src="EGRAM" no="43">
					<text>alanine may have blocked the action of a postulate repressor.</text>
					<arg n="0">alanine</arg>
					<arg n="1">the action of a postulate repressor</arg>
				</example>
				<example src="EGRAM" no="44">
					<text>alanine was able to block the action of a postulate suppressor.</text>
					<arg n="0">alanine</arg>
					<arg n="1">the action of a postulate suppressor</arg>
				</example>
				<example src="EGRAM" no="44">
					<text>alanine was able to block the action of a postulate suppressor.</text>
					<arg n="0">alanine</arg>
					<arg n="1">the action of a postulate suppressor</arg>
				</example>
				<example src="EGRAM" no="45">
					<text>0 (alanine) has been block as an inhibitor of the action of a recommended repressor.</text>
					<arg n="1">the action of a recommended repressor</arg>
				</example>
				<example src="EGRAM" no="45">
					<text>Alanine was believed to block the action of a postulate repressor.</text>
					<arg n="0">Alanine</arg>
					<arg n="1">the action of a postulate repressor</arg>
				</example>
				<example src="EGRAM" no="46">
					<text>alanine will block the action of a prescribed repressor.</text>
					<arg n="0">alanine</arg>
					<arg n="1">the action of a prescribed repressor</arg>
				</example>
				<example src="EGRAM" no="46">
					<text>alanine will block the action of a prescribed repressor.</text>
					<arg n="0">alanine</arg>
					<arg n="1">the action of a prescribed repressor</arg>
				</example>
				<example src="EGRAM" no="47">
					<text>alanine would block the action of a postulate repressor.</text>
					<arg n="0">alanine</arg>
					<arg n="1">the action of a postulate repressor</arg>
				</example>
				<example src="EGRAM" no="47">
					<text>alanine would block the action of a postulated repressor.</text>
					<arg n="0">alanine</arg>
					<arg n="1">the action of a postulated repressor</arg>
				</example>
				<example src="EGRAM" no="48">
					<text>Both RAP1 and RAP2 are important candidates for the vaccine, as antibodies to RAP1 is able to block merozoite invasion in vitro (Schofield et al., 1986; Harnyuttanakorn et al., 1992; Howard et al., 1998a).</text>
					<arg n="0">antibodies to RAP1</arg>
				</example>
				<example src="EGRAM" no="48">
					<text>Both RAP1 and 2 are important candidates in the vaccine because antibodies to RAP1 is shown to be able to block the invasion of merozoite in vitro (Schofield et al., 1986; Harnyuttanakorn et al., 1992; Howard et al., 1998a).</text>
					<arg n="0">antibodies to RAP1</arg>
				</example>
				<example src="EGRAM" no="49">
					<text>Both RAP1 and RAP2 are important candidates for vaccination, since antibody to RAP1 is shown to block invasion of merozoites in vitro (Schofield et al., 1986; Harnyuttanakorn et al., 1992; Howard et al., 1998a).</text>
					<arg n="0">antibody to RAP1</arg>
					<arg n="1">invasion of merozoites in vitro</arg>
				</example>
				<example src="EGRAM" no="49">
					<text>Both RAP1 and RAP2 are important candidates for vaccination, as antibodies to RAP1 are demonstrated to block invasion of merozoites in vitro (Schofield et al., 1986; Harnyuttanakorn et al., 1992; Howard et al., 1998a).</text>
					<arg n="0">antibodies to RAP1</arg>
					<arg n="1">invasion of merozoites in vitro</arg>
				</example>
				<example src="EGRAM" no="50">
					<text>Both RAP1 and RAP2 are important candidates for vaccination, as antibodies to RAP1 are blocked invasion of merozoites in vitro (Schofield et al., 1986; Harnyuttanakorn et al., 1992; Howard et al., 1998a).</text>
					<arg n="0">antibodies to RAP1</arg>
					<arg n="1">invasion of merozoites in vitro</arg>
				</example>
				<example src="EGRAM" no="50">
					<text>Both RAP1 and 2 are important candidates in the vaccine because antibodies to RAP1 is shown to have blocked invasion of merozoite in vitro (Schofield et al., 1986; Harnyuttanakorn et al., 1992; Howard et al., 1998a).</text>
					<arg n="0">antibodies to RAP1</arg>
					<arg n="1">invasion of merozoite in vitro</arg>
				</example>
				<example src="EGRAM" no="51">
					<text>Both RAP1 and 2 are important candidates in the vaccine because antibodies to RAP1 has been shown to be able to block invasion of merozoite in vitro (Schofield et al., 1986; Harnyuttanakorn et al., 1992; Howard et al., 1998a).</text>
					<arg n="0">antibodies to RAP1</arg>
					<arg n="1">invasion of merozoite in vitro</arg>
				</example>
				<example src="EGRAM" no="51">
					<text>Both RAP1 and RAP2 are important candidates for the vaccine, as antibodies to RAP1 has been shown to be able to block in vitro merozoite invasion (Schofield et al., 1986; Harnyuttanakorn et al., 1992; Howard et al., 1998a).</text>
					<arg n="0">antibodies to RAP1</arg>
					<arg n="1">in vitro merozoite invasion</arg>
				</example>
				<example src="EGRAM" no="52">
					<text>Both RAP1 and RAP2 are important candidates for vaccination, since antibody to RAP1 has been shown to block invasion of merozoites in vitro (Schofield et al., 1986; Harnyuttanakorn et al., 1992; Howard et al., 1998a).</text>
					<arg n="0">antibody to RAP1</arg>
					<arg n="1">invasion of merozoites in vitro</arg>
				</example>
				<example src="EGRAM" no="52">
					<text>Both RAP1 and RAP2 are important candidates for the vaccine, as antibodies to RAP1 has been shown to block in vitro merozoite invasion (Schofield et al., 1986; Harnyuttanakorn et al., 1992; Howard et al., 1998a).</text>
					<arg n="0">antibodies to RAP1</arg>
					<arg n="1">in vitro merozoite invasion</arg>
				</example>
				<example src="EGRAM" no="53">
					<text>Both RAP1 and RAP2 are important candidates for vaccination, since antibody to RAP1 has been shown to blocked invasion of merozoites in vitro (Schofield et al., 1986; Harnyuttanakorn et al., 1992; Howard et al., 1998a).</text>
					<arg n="0">antibody to RAP1</arg>
					<arg n="1">invasion of merozoites in vitro</arg>
				</example>
				<example src="EGRAM" no="53">
					<text>Both RAP1 and 2 are important candidates in the vaccine because antibodies to RAP1 has been shown to have blocked invasion of merozoite in vitro (Schofield et al., 1986; Harnyuttanakorn et al., 1992; Howard et al., 1998a).</text>
					<arg n="0">antibodies to RAP1</arg>
					<arg n="1">invasion of merozoite in vitro</arg>
				</example>
				<example src="EGRAM" no="54">
					<text>Both RAP1 and RAP2 are important candidates for the vaccine, as it has been block that antibodies to RAP1 block in vitro merozoite invasion (Schofield et al., 1986; Harnyuttanakorn et al., 1992; Howard et al., 1998a).</text>
					<arg n="0">antibodies to RAP1</arg>
					<arg n="1">in vitro merozoite invasion</arg>
				</example>
				<example src="EGRAM" no="54">
					<text>Both RAP1 and 2 are important candidates for the vaccine because it has been block that antibodies to RAP1 block invasion of merozoite in vitro (Schofield et al., 1986; Harnyuttanakorn et al., 1992; Howard et al., 1998a).</text>
					<arg n="0">antibodies to RAP1</arg>
					<arg n="1">invasion of merozoite in vitro</arg>
				</example>
				<example src="EGRAM" no="55">
					<text>Both RAP1 and RAP2 are important candidates for the vaccine, as it has been shown that antibodies to RAP1 blocked in vitro merozoite invasion (Schofield et al., 1986; Harnyuttanakorn et al., 1992; Howard et al., 1998a).</text>
					<arg n="0">antibodies to RAP1</arg>
					<arg n="1">in vitro merozoite invasion</arg>
				</example>
				<example src="EGRAM" no="55">
					<text>Both RAP1 and 2 are important candidates for the vaccine because it has been shown that antibodies to RAP1 blocked invasion of merozoite in vitro (Schofield et al., 1986; Harnyuttanakorn et al., 1992; Howard et al., 1998a).</text>
					<arg n="0">antibodies to RAP1</arg>
					<arg n="1">invasion of merozoite in vitro</arg>
				</example>
				<example src="EGRAM" no="56">
					<text>Both RAP1 and 2 are important candidates in the vaccine because it has been shown that antibodies to RAP1 can block invasion of merozoite in vitro (Schofield et al., 1986; Harnyuttanakorn et al., 1992; Howard et al., 1998a).</text>
					<arg n="0">antibodies to RAP1</arg>
					<arg n="1">invasion of merozoite in vitro</arg>
				</example>
				<example src="EGRAM" no="56">
					<text>Both RAP1 and RAP2 are important candidates for the vaccine, as it has been shown that antibodies to RAP1 can block in vitro merozoite invasion (Schofield et al., 1986; Harnyuttanakorn et al., 1992; Howard et al., 1998a).</text>
					<arg n="0">antibodies to RAP1</arg>
					<arg n="1">in vitro merozoite invasion</arg>
				</example>
				<example src="EGRAM" no="57">
					<text>Both RAP1 and 2 are important candidates in the vaccine because it has been shown that antibodies to RAP1 can block the invasion of merozoite in vitro (Schofield et al., 1986; Harnyuttanakorn et al., 1992; Howard et al., 1998a).</text>
					<arg n="0">antibodies to RAP1</arg>
				</example>
				<example src="EGRAM" no="57">
					<text>Both RAP1 and RAP2 are important candidates for the vaccine, as it has been shown that antibodies to RAP1 can block merozoite invasion in vitro (Schofield et al., 1986; Harnyuttanakorn et al., 1992; Howard et al., 1998a).</text>
					<arg n="0">antibodies to RAP1</arg>
				</example>
				<example src="EGRAM" no="58">
					<text>Both RAP1 and RAP2 are important candidates for the vaccine, as it has been shown that antibodies to RAP1 was able to block in vitro merozoite invasion (Schofield et al., 1986; Harnyuttanakorn et al., 1992; Howard et al., 1998a).</text>
					<arg n="0">antibodies to RAP1</arg>
					<arg n="1">in vitro merozoite invasion</arg>
				</example>
				<example src="EGRAM" no="58">
					<text>Both RAP1 and 2 are important candidates for the vaccine because it has been shown that antibodies to RAP1 was able to block invasion of merozoite in vitro (Schofield et al., 1986; Harnyuttanakorn et al., 1992; Howard et al., 1998a).</text>
					<arg n="0">antibodies to RAP1</arg>
					<arg n="1">invasion of merozoite in vitro</arg>
				</example>
				<example src="EGRAM" no="59">
					<text>Both RAP1 and 2 are important candidates for the vaccine because it has been shown that invasion of merozoite in vitro can be blocked by antibodies to RAP1 (Schofield et al., 1986; Harnyuttanakorn et al., 1992; Howard et al., 1998a).</text>
					<arg n="0">antibodies to RAP1</arg>
					<arg n="1">invasion of merozoite in vitro</arg>
				</example>
				<example src="EGRAM" no="59">
					<text>Both RAP1 and RAP2 are important candidates for the vaccine, as it has been shown that invasive merozoites in vitro can be blocked by antibodies to RAP1 (Schofield et al., 1986; Harnyuttanakorn et al., 1992; Howard et al., 1998a).</text>
					<arg n="0">antibodies to RAP1</arg>
					<arg n="1">invasive merozoites in vitro</arg>
				</example>
				<example src="EGRAM" no="60">
					<text>Both RAP1 and 2 are important candidates for the vaccine because it has been shown that invasion of merozoite in vitro could be blocked by antibodies to RAP1 (Schofield et al., 1986; Harnyuttanakorn et al., 1992; Howard et al., 1998a).</text>
					<arg n="0">antibodies to RAP1</arg>
					<arg n="1">invasion of merozoite in vitro</arg>
				</example>
				<example src="EGRAM" no="60">
					<text>Both RAP1 and RAP2 are important candidates for the vaccine, as it has been shown that in vitro merozoite invasion could be blocked by antibodies to RAP1 (Schofield et al., 1986; Harnyuttanakorn et al., 1992; Howard et al., 1998a).</text>
					<arg n="0">antibodies to RAP1</arg>
					<arg n="1">in vitro merozoite invasion</arg>
				</example>
				<example src="EGRAM" no="61">
					<text>Both RAP1 and RAP2 are important candidates for the vaccine, as it has been shown that in vitro merozoite invasion was blocked by antibodies to RAP1 (Schofield et al., 1986; Harnyuttanakorn et al., 1992; Howard et al., 1998a).</text>
					<arg n="0">antibodies to RAP1</arg>
					<arg n="1">in vitro merozoite invasion</arg>
				</example>
				<example src="EGRAM" no="61">
					<text>Both RAP1 and 2 are important candidates for the vaccine because it has been shown that invasion of merozoite in vitro has been blocked by antibodies to RAP1 (Schofield et al., 1986; Harnyuttanakorn et al., 1992; Howard et al., 1998a).</text>
					<arg n="0">antibodies to RAP1</arg>
					<arg n="1">invasion of merozoite in vitro</arg>
				</example>
				<example src="EGRAM" no="62">
					<text>Both RAP1 and RAP2 are important candidates for the vaccine, as it has been shown that in vitro merozoite invasion is blocked by antibodies to RAP1 (Schofield et al., 1986; Harnyuttanakorn et al., 1992; Howard et al., 1998a).</text>
					<arg n="0">antibodies to RAP1</arg>
					<arg n="1">in vitro merozoite invasion</arg>
				</example>
				<example src="EGRAM" no="62">
					<text>Both RAP1 and 2 are important candidates for the vaccine because it has been shown that invasion of merozoite in vitro is believed to be blocked by antibodies to RAP1 (Schofield et al., 1986; Harnyuttanakorn et al., 1992; Howard et al., 1998a).</text>
					<arg n="0">antibodies to RAP1</arg>
					<arg n="1">invasion of merozoite in vitro</arg>
				</example>
				<example src="EGRAM" no="63">
					<text>Both RAP1 and 2 are important candidates for the vaccine because it has been shown that invasion of merozoite in vitro is blocked by antibodies to RAP1 (Schofield et al., 1986; Harnyuttanakorn et al., 1992; Howard et al., 1998a).</text>
					<arg n="0">antibodies to RAP1</arg>
					<arg n="1">invasion of merozoite in vitro</arg>
				</example>
				<example src="EGRAM" no="63">
					<text>Both RAP1 and RAP2 are important candidates for the vaccine, as it has been shown that in vitro merozoite invasion is blocked by antibodies to RAP1 (Schofield et al., 1986; Harnyuttanakorn et al., 1992; Howard et al., 1998a).</text>
					<arg n="0">antibodies to RAP1</arg>
					<arg n="1">in vitro merozoite invasion</arg>
				</example>
				<example src="EGRAM" no="64">
					<text>Both RAP1 and 2 are important candidates for the vaccine because it has been shown that invasion of merozoite in vitro can be blocked by antibodies to RAP1 (Schofield et al., 1986; Harnyuttanakorn et al., 1992; Howard et al., 1998a).</text>
					<arg n="0">antibodies to RAP1</arg>
					<arg n="1">invasion of merozoite in vitro</arg>
				</example>
				<example src="EGRAM" no="64">
					<text>Both RAP1 and RAP2 are important candidates for the vaccine, as it has been shown that invasive merozoites in vitro can be blocked by antibodies to RAP1 (Schofield et al., 1986; Harnyuttanakorn et al., 1992; Howard et al., 1998a).</text>
					<arg n="0">antibodies to RAP1</arg>
					<arg n="1">invasive merozoites in vitro</arg>
				</example>
				<example src="EGRAM" no="65">
					<text>Both RAP1 and 2 are important candidates for the vaccine because it has been shown that invasion of merozoite in vitro could be blocked by antibodies to RAP1 (Schofield et al., 1986; Harnyuttanakorn et al., 1992; Howard et al., 1998a).</text>
					<arg n="0">antibodies to RAP1</arg>
					<arg n="1">invasion of merozoite in vitro</arg>
				</example>
				<example src="EGRAM" no="65">
					<text>Both RAP1 and RAP2 are important candidates for the vaccine, as it has been shown that in vitro merozoite invasion could be blocked by antibodies to RAP1 (Schofield et al., 1986; Harnyuttanakorn et al., 1992; Howard et al., 1998a).</text>
					<arg n="0">antibodies to RAP1</arg>
					<arg n="1">in vitro merozoite invasion</arg>
				</example>
				<example src="EGRAM" no="66">
					<text>Both RAP1 and RAP2 are important candidates for the vaccine, as it has been shown that in vitro merozoite invasion has been blocked by antibodies to RAP1 (Schofield et al., 1986; Harnyuttanakorn et al., 1992; Howard et al., 1998a).</text>
					<arg n="0">antibodies to RAP1</arg>
					<arg n="1">in vitro merozoite invasion</arg>
				</example>
				<example src="EGRAM" no="66">
					<text>Both RAP1 and 2 are important candidates for the vaccine because it has been shown that invasion of merozoite in vitro was believed to be blocked by antibodies to RAP1 (Schofield et al., 1986; Harnyuttanakorn et al., 1992; Howard et al., 1998a).</text>
					<arg n="0">antibodies to RAP1</arg>
					<arg n="1">invasion of merozoite in vitro</arg>
				</example>
				<example src="EGRAM" no="67">
					<text>Both RAP1 and 2 are important candidates for the vaccine because it has been shown that invasion of merozoite in vitro was blocked by antibodies to RAP1 (Schofield et al., 1986; Harnyuttanakorn et al., 1992; Howard et al., 1998a).</text>
					<arg n="0">antibodies to RAP1</arg>
					<arg n="1">invasion of merozoite in vitro</arg>
				</example>
				<example src="EGRAM" no="67">
					<text>Both RAP1 and RAP2 are important candidates for the vaccine, as it has been shown that in vitro merozoite invasion was blocked by antibodies to RAP1 (Schofield et al., 1986; Harnyuttanakorn et al., 1992; Howard et al., 1998a).</text>
					<arg n="0">antibodies to RAP1</arg>
					<arg n="1">in vitro merozoite invasion</arg>
				</example>
				<example src="EGRAM" no="68">
					<text>Both RAP1 and 2 are important candidates for the vaccine because it has been shown that invasion of merozoite in vitro will be blocked by antibodies to RAP1 (Schofield et al., 1986; Harnyuttanakorn et al., 1992; Howard et al., 1998a).</text>
					<arg n="0">antibodies to RAP1</arg>
					<arg n="1">invasion of merozoite in vitro</arg>
				</example>
				<example src="EGRAM" no="68">
					<text>Both RAP1 and RAP2 are important candidates for the vaccine, as it has been shown that in vitro merozoite invasion will be blocked by antibodies to RAP1 (Schofield et al., 1986; Harnyuttanakorn et al., 1992; Howard et al., 1998a).</text>
					<arg n="0">antibodies to RAP1</arg>
					<arg n="1">in vitro merozoite invasion</arg>
				</example>
				<example src="EGRAM" no="69">
					<text>Both RAP1 and 2 are important candidates for the vaccine because it has been shown that invasion of merozoite in vitro would be blocked by antibodies to RAP1 (Schofield et al., 1986; Harnyuttanakorn et al., 1992; Howard et al., 1998a).</text>
					<arg n="0">antibodies to RAP1</arg>
					<arg n="1">invasion of merozoite in vitro</arg>
				</example>
				<example src="EGRAM" no="69">
					<text>Both RAP1 and RAP2 are important candidates for the vaccine, as it has been shown that in vitro merozoite invasion would be blocked by antibodies to RAP1 (Schofield et al., 1986; Harnyuttanakorn et al., 1992; Howard et al., 1998a).</text>
					<arg n="0">antibodies to RAP1</arg>
					<arg n="1">in vitro merozoite invasion</arg>
				</example>
				<example src="EGRAM" no="70">
					<text>Both RAP1 and RAP2 are important candidates for vaccination, as in vitro merozoid invasion is blocked by antibodies to RAP1 (Schofield et al., 1986; Harnyuttanakorn et al., 1992; Howard et al., 1998a).</text>
					<arg n="0">antibodies to RAP1</arg>
					<arg n="1">in vitro merozoid invasion</arg>
				</example>
				<example src="EGRAM" no="70">
					<text>Both RAP1 and RAP2 are important candidates for the vaccine, as in vitro merozoite invasion is blocked by antibodies to RAP1 (Schofield et al., 1986; Harnyuttanakorn et al., 1992; Howard et al., 1998a).</text>
					<arg n="0">antibodies to RAP1</arg>
					<arg n="1">in vitro merozoite invasion</arg>
				</example>
				<example src="EGRAM" no="71">
					<text>Both RAP1 and RAP2 are important candidates for vaccination, as in vitro merozoite invasion has been shown to be blocked by antibodies to RAP1 (Schofield et al., 1986; Harnyuttanakorn et al., 1992; Howard et al., 1998a).</text>
					<arg n="0">antibodies to RAP1</arg>
					<arg n="1">in vitro merozoite invasion</arg>
				</example>
				<example src="EGRAM" no="71">
					<text>Both RAP1 and RAP2 are important candidates for vaccination, as in vitro merozoid invasion has been shown to have been blocked by antibodies to RAP1 (Schofield et al., 1986; Harnyuttanakorn et al., 1992; Howard et al., 1998a).</text>
					<arg n="0">antibodies to RAP1</arg>
					<arg n="1">in vitro merozoid invasion</arg>
				</example>
				<example src="EGRAM" no="72">
					<text>Both RAP1 and 2 are important candidates in the vaccine because invasion of merozoite in vitro was blocked by antibodies to RAP1 (Schofield et al., 1986; Harnyuttanakorn et al., 1992; Howard et al., 1998a).</text>
					<arg n="0">antibodies to RAP1</arg>
					<arg n="1">invasion of merozoite in vitro</arg>
				</example>
				<example src="EGRAM" no="72">
					<text>Both RAP1 and RAP2 are important candidates for the vaccine, as in vitro merozoite invasion was blocked by antibodies to RAP1 (Schofield et al., 1986; Harnyuttanakorn et al., 1992; Howard et al., 1998a).</text>
					<arg n="0">antibodies to RAP1</arg>
					<arg n="1">in vitro merozoite invasion</arg>
				</example>
				<example src="EGRAM" no="73">
					<text>Both RAP1 and 2 are important candidates in the vaccine because invasion of merozoite in vitro was blocked by antibodies to RAP1 (Schofield et al., 1986; Harnyuttanakorn et al., 1992; Howard et al., 1998a).</text>
					<arg n="0">antibodies to RAP1</arg>
					<arg n="1">invasion of merozoite in vitro</arg>
				</example>
				<example src="EGRAM" no="73">
					<text>Both RAP1 and RAP2 are important candidates for the vaccine, as in vitro merozoite invasion was blocked by antibodies to RAP1 (Schofield et al., 1986; Harnyuttanakorn et al., 1992; Howard et al., 1998a).</text>
					<arg n="0">antibodies to RAP1</arg>
					<arg n="1">in vitro merozoite invasion</arg>
				</example>
				<example src="EGRAM" no="74">
					<text>It blocked Memberans in TBST (standard serum tris, 0.05% Tween-20) which contains 5% serum albumin (for antiphosphorycine stains) or skimmed milk and antibody-provided.</text>
					<arg n="1">Memberans</arg>
				</example>
				<example src="EGRAM" no="74">
					<text>It blocked Memory in TBST (Tris-buffered saline, 0.05% Tween-20) which contained 5% of beef serum albumin (for antiphosphorosine rostes) or skimmed milk and antibody polled.</text>
					<arg n="1">Memory</arg>
				</example>
				<example src="EGRAM" no="75">
					<text>Block membranes in TBST (Tris-buffered saline, 0.05% Tween-20) blocks 5% of beef serum albumin (for antiphosphorosine rostes) or skimmed milk and antibody polled.</text>
					<arg n="1">membranes</arg>
				</example>
				<example src="EGRAM" no="75">
					<text>Membranes blocks TBST (tris buffer serum, 0.05% Tween-20) blocks 5% bovine serum albumin (for antiphosphorycin stains) or skimmed milk and was submitted to enzyme-linked immunosorbent tests.</text>
					<arg n="1">Membranes</arg>
				</example>
				<example src="EGRAM" no="76">
					<text>It may block Membranes in TBST (Two-fold buffer serum, 0.05% Tween-20) containing 5% bovine serum albumin (for antiphosphorycin spots) or skimmed and antibody-probed milk.</text>
					<arg n="1">Membranes</arg>
				</example>
				<example src="EGRAM" no="76">
					<text>It can block membranes in TBST (Tris-buffered saline, 0.05% Tween-20) containing 5% of serum albumin (for antiphosphorosine blockers) or skimmed milk and antibody-sounded.</text>
					<arg n="1">membranes</arg>
				</example>
				<example src="EGRAM" no="77">
					<text>It can block Membranes in TBST (Tween-20 0.05% buffer serum) containing 5% beef serum albumin (for antiphosphorycine stains) or skimmed milk and antibody-propelled.</text>
					<arg n="1">Membranes</arg>
				</example>
				<example src="EGRAM" no="77">
					<text>It could block membranes in TBST (Tris-buffered saline, 0.05% Tween-20) containing 5% of beef serum albumin (for antiphosphorosine blockers) or skimmed milk and antibody polled.</text>
					<arg n="1">membranes</arg>
				</example>
				<example src="EGRAM" no="78">
					<text>It blocked Membranes in TBST (triple serum, 0.05% Tween-20) containing 5% of serum albumin (for antiphosphorycin stains) or skimmed milk and antibody-provided.</text>
					<arg n="1">Membranes</arg>
				</example>
				<example src="EGRAM" no="78">
					<text>It has blocked Memory in TBST (Tris-buffered saline, 0.05% Tween-20) which contains 5% of beef serum albumin (for antiphosphorosine rostes) or skimmed milk and antibody polled.</text>
					<arg n="1">Memory</arg>
				</example>
				<example src="EGRAM" no="79">
					<text>It is able to block Membranes in TBST (tris buffer serum, 0.05% Tween-20) containing 5% bovine serum albumin (for antiphosphorycin spots) or skimmed and antibody-probed milk.</text>
					<arg n="1">Membranes</arg>
				</example>
				<example src="EGRAM" no="79">
					<text>It is able to block membranes in TBST (Tris-buffered saline, 0.05% Tween-20) containing 5% of beef serum albumin (for antiphosphorosine rostes) or skimmed milk and antibody polled.</text>
					<arg n="1">membranes</arg>
				</example>
				<example src="EGRAM" no="80">
					<text>It is thought to block Memberans in TBST (duck buffer trits, 0.05% Tween-20) containing 5% of the serum albumin bovine (for antiphosphorycine stains) or skimmed milk and is sounded with antibody.</text>
					<arg n="1">Memberans</arg>
				</example>
				<example src="EGRAM" no="80">
					<text>It is thought to block membranes in TBST (Tris-buffered saline, 0.05% Tween-20) containing 5% of beef serum albumin (for antiphosphorosine rostes) or skimmed milk and antibody polled.</text>
					<arg n="1">membranes</arg>
				</example>
				<example src="EGRAM" no="81">
					<text>It may block Membranes in TBST (Two-fold buffer serum, 0.05% Tween-20) containing 5% bovine serum albumin (for antiphosphorycin spots) or skimmed and antibody-probed milk.</text>
					<arg n="1">Membranes</arg>
				</example>
				<example src="EGRAM" no="81">
					<text>It can block membranes in TBST (Tris-buffered saline, 0.05% Tween-20) which contains 5% serum albumin (for antiphosphorosine blockers) or skimmed milk and antibody-sounded.</text>
					<arg n="1">membranes</arg>
				</example>
				<example src="EGRAM" no="82">
					<text>It may block Membranes in TBST (Two-fold buffer serum, 0.05% Tween-20) containing 5% bovine serum albumin (for antiphosphorycin spots) or skimmed and antibody-probed milk.</text>
					<arg n="1">Membranes</arg>
				</example>
				<example src="EGRAM" no="82">
					<text>It could block membranes in TBST (Tris-buffered saline, 0.05% Tween-20) containing 5% of beef serum albumin (for antiphosphorosine blockers) or skimmed milk and antibody polled.</text>
					<arg n="1">membranes</arg>
				</example>
				<example src="EGRAM" no="83">
					<text>It was able to block Membranes in TBST (trise serum, 0.05% Tween-20) containing 5% of serum albumin beef (for antiphosphorycine stains) or skimmed milk and underwent enzyme-linked immunosorbent testing.</text>
					<arg n="1">Membranes</arg>
				</example>
				<example src="EGRAM" no="83">
					<text>It was able to block Membranes in TBST (tris buffer serum, 0.05% Tween-20) containing 5% bovine serum albumin (for antiphosphorycin stains) or skimmed milk and was submitted to enzyme-linked immunosorbent tests.</text>
					<arg n="1">Membranes</arg>
				</example>
				<example src="EGRAM" no="84">
					<text>It is believed to block Membranes in TBST (buffered room tris, 0.05% Tween-20) containing 5% of bovine serum albumin (for antiphosphorycin spots) or skimmed milk and was probed with antibodies.</text>
					<arg n="1">Membranes</arg>
				</example>
				<example src="EGRAM" no="84">
					<text>It was believed to block membranes in TBST (Tris-buffered saline, 0.05% Tween-20) containing 5% of beef serum albumin (for antiphosphorosine rostes) or skimmed milk and antibody-sounded.</text>
					<arg n="1">membranes</arg>
				</example>
				<example src="EGRAM" no="85">
					<text>Block Memory in TBST (Tris-buffered saline, 0.05% Tween-20) block 5% of beef serum albumin (for antiphosphorosine blots) or skimmed milk and antibody polled.</text>
					<arg n="1">Memory</arg>
				</example>
				<example src="EGRAM" no="85">
					<text>It blocks Membranes in TBST (standard tris serum, 0.05% Tween-20) containing 5% bovine serum albumin (for antiphosphorycin spots) or skimmed milk and probed with antibodies.</text>
					<arg n="1">Membranes</arg>
				</example>
				<example src="EGRAM" no="86">
					<text>It blocks Membranes in TBST (tris-paced serum, 0.05% Tween-20) containing 5% bovine serum albumin (for antiphosphorycin patches) or skimmed milk and probed with antibodies.</text>
					<arg n="1">Membranes</arg>
				</example>
				<example src="EGRAM" no="86">
					<text>It would block membranes in TBST (Tris-buffered saline, 0.05% Tween-20) containing 5% of beef serum albumin (for antiphosphorosine rostes) or skimmed milk and antibody polled.</text>
					<arg n="1">membranes</arg>
				</example>
				<example src="EGRAM" no="87">
					<text>The labelling with antibodies against phosphopeptide Y553 is specific, since labelling can be blocked by pre-incubation of antibodies with phosphopeptide.</text>
					<arg n="0">pre-incubation of antibodies with phosphopeptide</arg>
					<arg n="1">labelling</arg>
				</example>
				<example src="EGRAM" no="87">
					<text>The antibody labelling in the Y553 phosphopeptide is specific, since taging can be blocked by pre-incubation of antibodies with phosphopeptide.</text>
					<arg n="0">pre-incubation of antibodies with phosphopeptide</arg>
					<arg n="1">taging</arg>
				</example>
				<example src="EGRAM" no="88">
					<text>The labelling with antibodies against the phosphopeptide Y553 is specific, since labelling is capable of being blocked by pre-incubation of antibodies with the phosphopeptide.</text>
					<arg n="0">pre-incubation of antibodies with the phosphopeptide</arg>
					<arg n="1">labelling</arg>
				</example>
				<example src="EGRAM" no="88">
					<text>Antibody tagging against phosphopeptide Y553 is specific, since labeling is able to be blocked by pre-incubation of antibody with phosphopeptide.</text>
					<arg n="0">pre-incubation of antibody with phosphopeptide</arg>
					<arg n="1">labeling</arg>
				</example>
				<example src="EGRAM" no="89">
					<text>The labelling of antibodies in the Y553 phosphopeptide is specific, since labelling is believed to be blocked by preincubation of antibodies with phosphopeptide.</text>
					<arg n="0">preincubation of antibodies with phosphopeptide</arg>
					<arg n="1">labelling</arg>
				</example>
				<example src="EGRAM" no="89">
					<text>The labelling with antibodies against phosphopeptide Y553 is specific, since labelling is believed to be blocked by pre-incubation of antibodies with phosphopeptide.</text>
					<arg n="0">pre-incubation of antibodies with phosphopeptide</arg>
					<arg n="1">labelling</arg>
				</example>
				<example src="EGRAM" no="90">
					<text>The labelling with antibodies for phosphopeptide Y553 is specific, since pre-incubation of antibodies with phosphopeptide blocked labelling.</text>
					<arg n="0">pre-incubation of antibodies with phosphopeptide</arg>
					<arg n="1">labelling</arg>
				</example>
				<example src="EGRAM" no="90">
					<text>The antibody labeling in the Y553 phosphopeptide is specific, since pre-incubation of antibodies with phosphopeptide blocked labelling.</text>
					<arg n="0">pre-incubation of antibodies with phosphopeptide</arg>
					<arg n="1">labelling</arg>
				</example>
				<example src="EGRAM" no="91">
					<text>The labelling with antibodies for phosphopeptide Y553 blocks specific, since pre-incubation of antibodies with phosphopeptide blocks labelling.</text>
					<arg n="0">pre-incubation of antibodies with phosphopeptide</arg>
					<arg n="1">labelling</arg>
				</example>
				<example src="EGRAM" no="91">
					<text>The labelling of antibodies in the Y553 phosphopeptide is specific to A0 blockades (pre-incubation of antibodies with phosphopeptide) (blocks).</text>
				</example>
				<example src="EGRAM" no="92">
					<text>The antibody labelling in the Y553 phosphopeptide is specific, since pre-incubation of antibodies with phosphopeptide may block labelling.</text>
					<arg n="0">pre-incubation of antibodies with phosphopeptide</arg>
					<arg n="1">labelling</arg>
				</example>
				<example src="EGRAM" no="92">
					<text>The labelling with antibodies to phosphopeptide Y553 is specific, since pre-incubation of antibodies with phosphopeptide may block labelling.</text>
					<arg n="0">pre-incubation of antibodies with phosphopeptide</arg>
					<arg n="1">labelling</arg>
				</example>
				<example src="EGRAM" no="93">
					<text>The labelling with antibodies for phosphopeptide Y553 is specific, since pre-incubation of antibodies with phosphopeptide may have blocked labelling.</text>
					<arg n="0">pre-incubation of antibodies with phosphopeptide</arg>
					<arg n="1">labelling</arg>
				</example>
				<example src="EGRAM" no="93">
					<text>The labelling of antibodies in the Y553 phosphopeptide is specific, since pre-incubation of antibodies with phosphopeptide may have blocked labelling.</text>
					<arg n="0">pre-incubation of antibodies with phosphopeptide</arg>
					<arg n="1">labelling</arg>
				</example>
				<example src="EGRAM" no="94">
					<text>The antibody labelling in the Y553 phosphopeptide is specific, since pre-incubation of antibodies with phosphopeptide blocked label.</text>
					<arg n="0">pre-incubation of antibodies with phosphopeptide</arg>
					<arg n="1">label</arg>
				</example>
				<example src="EGRAM" no="94">
					<text>The labelling with antibodies for phosphopeptide Y553 is specific, since pre-incubation of antibodies with phosphopeptide blocked labelling.</text>
					<arg n="0">pre-incubation of antibodies with phosphopeptide</arg>
					<arg n="1">labelling</arg>
				</example>
				<example src="EGRAM" no="95">
					<text>The labelling of antibodies in the Y553 phosphopeptide is specific, since pre-incubation of antibodies with phosphopeptide is able to block label.</text>
					<arg n="0">pre-incubation of antibodies with phosphopeptide</arg>
					<arg n="1">label</arg>
				</example>
				<example src="EGRAM" no="95">
					<text>The labelling with antibodies to phosphopeptide Y553 is specific, since pre-incubation of antibodies with phosphopeptide is able to block labelling.</text>
					<arg n="0">pre-incubation of antibodies with phosphopeptide</arg>
					<arg n="1">labelling</arg>
				</example>
				<example src="EGRAM" no="96">
					<text>The labelling with antibodies against phosphopeptide Y553 is specific, since pre-incubation of antibodies with phosphopeptide may block labelling.</text>
					<arg n="0">pre-incubation of antibodies with phosphopeptide</arg>
					<arg n="1">labelling</arg>
				</example>
				<example src="EGRAM" no="96">
					<text>The labelling of antibodies in the Y553 phosphopeptide is specific, since pre-incubation of antibodies with phosphopeptide may block labelling.</text>
					<arg n="0">pre-incubation of antibodies with phosphopeptide</arg>
					<arg n="1">labelling</arg>
				</example>
				<example src="EGRAM" no="97">
					<text>The labelling with antibodies for phosphopeptide Y553 is specific, since pre-incubation of antibodies with phosphopeptide may have blocked labelling.</text>
					<arg n="0">pre-incubation of antibodies with phosphopeptide</arg>
					<arg n="1">labelling</arg>
				</example>
				<example src="EGRAM" no="97">
					<text>The labelling of antibodies in the Y553 phosphopeptide is specific, since pre-incubation of antibodies with phosphopeptide may have blocked labelling.</text>
					<arg n="0">pre-incubation of antibodies with phosphopeptide</arg>
					<arg n="1">labelling</arg>
				</example>
				<example src="EGRAM" no="98">
					<text>The labelling with antibodies for phosphopeptide Y553 is specific, since pre-incubation of antibodies with phosphopeptide will block labelling.</text>
					<arg n="0">pre-incubation of antibodies with phosphopeptide</arg>
					<arg n="1">labelling</arg>
				</example>
				<example src="EGRAM" no="98">
					<text>The labeling of antibodies in the Y553 phosphopeptide is specific, since pre-incubation of antibodies with phosphopeptide will block labelling.</text>
					<arg n="0">pre-incubation of antibodies with phosphopeptide</arg>
					<arg n="1">labelling</arg>
				</example>
				<example src="EGRAM" no="99">
					<text>The antibody labeling in the Y553 phosphopeptide was specific, since labelled can be blocked by pre-incubation of antibodies with phosphopeptide.</text>
					<arg n="0">pre-incubation of antibodies with phosphopeptide</arg>
					<arg n="1">labelled</arg>
				</example>
				<example src="EGRAM" no="99">
					<text>The antibody labeling for the phosphopeptide Y553 was specific, since labelling can be blocked by pre-incubation of antibodies with phosphopeptide.</text>
					<arg n="0">pre-incubation of antibodies with phosphopeptide</arg>
					<arg n="1">labelling</arg>
				</example>
				<example src="EGRAM" no="100">
					<text>Antibody labelling for the phosphopeptide Y553 was specific, as labelling was blocked by pre-incubation of antibody with phosphopeptide.</text>
					<arg n="0">pre-incubation of antibody with phosphopeptide</arg>
					<arg n="1">labelling</arg>
				</example>
				<example src="EGRAM" no="100">
					<text>The antibody labeling for the phosphopeptide Y553 was specific, since labeling was blocked by pre-incubation of antibodies with phosphopeptide.</text>
					<arg n="0">pre-incubation of antibodies with phosphopeptide</arg>
					<arg n="1">labeling</arg>
				</example>
				<example src="EGRAM" no="101">
					<text>Antibody labelling for the phosphopeptide Y553 was specific, since labelling was able to be blocked by pre-incubation of antibody with phosphopeptide.</text>
					<arg n="0">pre-incubation of antibody with phosphopeptide</arg>
					<arg n="1">labelling</arg>
				</example>
				<example src="EGRAM" no="101">
					<text>The antibody labeling for the phosphopeptide Y553 was specific, since labeling was able to be blocked by pre-incubation of antibodies with phosphopeptide.</text>
					<arg n="0">pre-incubation of antibodies with phosphopeptide</arg>
					<arg n="1">labeling</arg>
				</example>
				<example src="EGRAM" no="102">
					<text>Antibody tagging in the Y553 phosphopeptide was specific, as taging was believed to be blocked by preincubation of antibody with phosphopeptide.</text>
					<arg n="0">preincubation of antibody with phosphopeptide</arg>
					<arg n="1">taging</arg>
				</example>
				<example src="EGRAM" no="102">
					<text>Antibody tagging for the phosphopeptide Y553 was specific, because labelling is believed to be blocked by preincubation of antibody with phosphopeptide.</text>
					<arg n="0">preincubation of antibody with phosphopeptide</arg>
					<arg n="1">labelling</arg>
				</example>
				<example src="EGRAM" no="103">
					<text>Antibody labelling for the phosphopeptide Y553 was specific, as labelling was blocked by pre-incubation of antibody with phosphopeptide.</text>
					<arg n="0">pre-incubation of antibody with phosphopeptide</arg>
					<arg n="1">labelling</arg>
				</example>
				<example src="EGRAM" no="103">
					<text>The antibody labeling for the phosphopeptide Y553 was specific, since labeling was blocked by pre-incubation of antibodies with phosphopeptide.</text>
					<arg n="0">pre-incubation of antibodies with phosphopeptide</arg>
					<arg n="1">labeling</arg>
				</example>
				<example src="EGRAM" no="104">
					<text>The antibody labeling in the Y553 phosphopeptide was specific, as pre-incubation of antibodies with phosphopeptide could block labelling.</text>
					<arg n="0">pre-incubation of antibodies with phosphopeptide</arg>
					<arg n="1">labelling</arg>
				</example>
				<example src="EGRAM" no="104">
					<text>The antibody labeling for the phosphopeptide Y553 was specific, as pre-incubation of antibodies with phosphopeptide could block labeling.</text>
					<arg n="0">pre-incubation of antibodies with phosphopeptide</arg>
					<arg n="1">labeling</arg>
				</example>
				<example src="EGRAM" no="105">
					<text>The antibody labeling in the Y553 phosphopeptide was specific, since pre-incubation of antibodies with phosphopeptide could have blocked label.</text>
					<arg n="0">pre-incubation of antibodies with phosphopeptide</arg>
					<arg n="1">label</arg>
				</example>
				<example src="EGRAM" no="105">
					<text>The antibody labeling for the phosphopeptide Y553 was specific, as pre-incubation of antibodies with phosphopeptide could have blocked labeling.</text>
					<arg n="0">pre-incubation of antibodies with phosphopeptide</arg>
					<arg n="1">labeling</arg>
				</example>
				<example src="EGRAM" no="106">
					<text>The antibody labeling in the Y553 phosphopeptide was specific, as pre-incubation of antibodies with phosphopeptide could block labelling.</text>
					<arg n="0">pre-incubation of antibodies with phosphopeptide</arg>
					<arg n="1">labelling</arg>
				</example>
				<example src="EGRAM" no="106">
					<text>The antibody labeling for the phosphopeptide Y553 was specific, as pre-incubation of antibodies with phosphopeptide may block labelling.</text>
					<arg n="0">pre-incubation of antibodies with phosphopeptide</arg>
					<arg n="1">labelling</arg>
				</example>
				<example src="EGRAM" no="107">
					<text>The antibody labeling in the Y553 phosphopeptide was specific, since pre-incubation of antibodies with phosphopeptide could have blocked label.</text>
					<arg n="0">pre-incubation of antibodies with phosphopeptide</arg>
					<arg n="1">label</arg>
				</example>
				<example src="EGRAM" no="107">
					<text>The antibody labeling for the phosphopeptide Y553 was specific, as pre-incubation of antibodies with phosphopeptide may have blocked labeling.</text>
					<arg n="0">pre-incubation of antibodies with phosphopeptide</arg>
					<arg n="1">labeling</arg>
				</example>
				<example src="EGRAM" no="108">
					<text>The antibody labeling in the Y553 phosphopeptide was specific, as pre-incubation of antibodies with phosphopeptide was able to block label.</text>
					<arg n="0">pre-incubation of antibodies with phosphopeptide</arg>
					<arg n="1">label</arg>
				</example>
				<example src="EGRAM" no="108">
					<text>The antibody labeling for the phosphopeptide Y553 was specific, as pre-incubation of antibodies with phosphopeptide was able to block labeling.</text>
					<arg n="0">pre-incubation of antibodies with phosphopeptide</arg>
					<arg n="1">labeling</arg>
				</example>
				<example src="EGRAM" no="109">
					<text>The antibody labeling in the Y553 phosphopeptide was specific, as pre-incubation of antibodies with phosphopeptide would block labelling.</text>
					<arg n="0">pre-incubation of antibodies with phosphopeptide</arg>
					<arg n="1">labelling</arg>
				</example>
				<example src="EGRAM" no="109">
					<text>The antibody labeling for the phosphopeptide Y553 was specific, as pre-incubation of antibodies with phosphopeptide would block labeling.</text>
					<arg n="0">pre-incubation of antibodies with phosphopeptide</arg>
					<arg n="1">labeling</arg>
				</example>
				<example src="EGRAM" no="110">
					<text>The antibody labeling in the Y553 phosphopeptide was specific, since pre-incubation of antibodies with phosphopeptide would have blocked label.</text>
					<arg n="0">pre-incubation of antibodies with phosphopeptide</arg>
					<arg n="1">label</arg>
				</example>
				<example src="EGRAM" no="110">
					<text>The antibody labeling for the phosphopeptide Y553 was specific, as pre-incubation of antibodies with phosphopeptide would have blocked labeling.</text>
					<arg n="0">pre-incubation of antibodies with phosphopeptide</arg>
					<arg n="1">labeling</arg>
				</example>
				<example src="EGRAM" no="111">
					<text>Membranes is able to be blocked in TBST (standard tris serum, 0.05% Tween-20) containing 5% serum albumin (for antiphosphorycine stains) or skimmed milk and antibody-sounded.</text>
					<arg n="1">Membranes</arg>
				</example>
				<example src="EGRAM" no="111">
					<text>Membranes is able to be blocked in TBST (standard tris serum, 0.05% Tween-20) containing 5% bovine serum albumin (for antiphosphorycin spots) or skimmed milk and probed with antibodies.</text>
					<arg n="1">Membranes</arg>
				</example>
				<example src="EGRAM" no="112">
					<text>Membranes is considered to be blocked in TBST (standard tris serum, 0.05% Tween-20) containing 5% bovine serum albumin (for antiphosphorycin spots) or skimmed milk probed with antibodies.</text>
					<arg n="1">Membranes</arg>
				</example>
				<example src="EGRAM" no="112">
					<text>membranes is believed to be blocked in TBST (Saline tris-buffered, 0.05% Tween-20) containing 5% of beef serum albumin (for antiphosphorosine flutes) or skimmed milk and antibody-sounded.</text>
					<arg n="1">membranes</arg>
				</example>
				<example src="EGRAM" no="113">
					<text>Membranes is blocked in TBST (tris buffer serum, 0.05% Tween-20) containing 5% bovine serum albumin (for antiphosphorycin spots) or skimmed milk and probed with antibodies.</text>
					<arg n="1">Membranes</arg>
				</example>
				<example src="EGRAM" no="113">
					<text>Memoirs are blocked in TBST (Tris-buffered saline, 0.05% Tween-20) containing 5% of beef serum albumin (for antiphosphorosine flutes) or skimmed milk and antibody-sounded.</text>
					<arg n="1">Memoirs</arg>
				</example>
				<example src="EGRAM" no="114">
					<text>membranes can be blocked in TBST (Saline tris-buffered, 0.05% Tween-20) containing 5% of beef serum albumin (for antiphosphorosine rostes) or skimmed milk and antibody polled.</text>
					<arg n="1">membranes</arg>
				</example>
				<example src="EGRAM" no="114">
					<text>membranes can be blocked in TBST (tris-slurred with saline solution, 0.05% Tween-20) containing 5% of serum albumin from beef (for antiphosphorosin rostes) or skimmed milk and polished antibodies.</text>
					<arg n="1">membranes</arg>
				</example>
				<example src="EGRAM" no="115">
					<text>membranes was blocked in TBST (tris-standard serum, 0.05% Tween-20), which contains 5% of serum albumin from beef (for antiphosphorosin rostes) or skimmed milk and polished antibodies.</text>
					<arg n="1">membranes</arg>
				</example>
				<example src="EGRAM" no="115">
					<text>membranes has been blocked in TBST (Tris-buffered saline, 0.05% Tween-20) which contains 5% of beef serum albumin (for antiphosphorosine rostes) or skimmed milk and antibody polled.</text>
					<arg n="1">membranes</arg>
				</example>
				<example src="EGRAM" no="116">
					<text>membranes can be blocked in TBST (Saline tris-buffered, 0.05% Tween-20) containing 5% of beef serum albumin (for antiphosphorosine rostes) or skimmed milk and antibody polled.</text>
					<arg n="1">membranes</arg>
				</example>
				<example src="EGRAM" no="116">
					<text>membranes can be blocked in TBST (tris-slurred with saline solution, 0.05% Tween-20) containing 5% of serum albumin from beef (for antiphosphorosin rostes) or skimmed milk and polished antibodies.</text>
					<arg n="1">membranes</arg>
				</example>
				<example src="EGRAM" no="117">
					<text>membranes will be blocked in TBST (Salina tris-buffered, 0.05% Tween-20) containing 5% of beef serum albumin (for antiphosphorosine rostes) or skimmed milk and antibody polled.</text>
					<arg n="1">membranes</arg>
				</example>
				<example src="EGRAM" no="117">
					<text>Membranes will be blocked in TBST (standard tris serum, 0.05% Tween-20) containing 5% bovine serum albumin (for antiphosphorycin spots) or skimmed milk and probed with antibodies.</text>
					<arg n="1">Membranes</arg>
				</example>
				<example src="EGRAM" no="118">
					<text> Mutations in site 3 splice that is able to specifically block step II do not affect the association of hPrps 16 and 17 with spliceosome, indicating that these factors can function at a stage of step II before the recognition of the site 3 splice.</text>
					<arg n="0"> Mutations in site 3 splice</arg>
					<arg n="1">step II</arg>
				</example>
				<example src="EGRAM" no="118">
					<text>The mutations of the cutting site that is able to specifically block step II does not affect the association of hPrps 16 and 17 with the sliceosome, indicating that these factors can work in a phase of step II before the recognition of the 3-cut site.</text>
					<arg n="0">mutations of the cutting site</arg>
					<arg n="1">step II</arg>
				</example>
				<example src="EGRAM" no="119">
					<text>3-slice site mutations is thought to have no effect on the association of hPrps 16 and 17 with sclerosis, block that these factors may work at a phase of of 2 before the 3-slice site recognition.</text>
					<arg n="0">3-slice site mutations</arg>
					<arg n="1">of 2</arg>
				</example>
				<example src="EGRAM" no="119">
					<text> Mutations at the site of 3 splice is thought to have no effect on the association of hPrps 16 and 17 with spliceosome, indicating that these factors can block at a stage of step II before the recognition of the site of 3 splices.</text>
					<arg n="0"> Mutations at the site of 3 splice</arg>
					<arg n="1">step II</arg>
				</example>
				<example src="EGRAM" no="120">
					<text>mutations of the inflection site specifically blocking step II does not affect the association of hPrps 16 and 17 with splennosoma, indicating that these factors can work in a phase of step II before recognition of the inflection site.</text>
					<arg n="0">mutations of the inflection site</arg>
					<arg n="1">step II</arg>
				</example>
				<example src="EGRAM" no="120">
					<text> Mutations at site 3 splice specifically blocking step II do not affect the association of hPrps 16 and 17 with the spliceosome, indicating that these factors can function at a stage of step II before the recognition of the site 3 splice.</text>
					<arg n="0"> Mutations at site 3 splice</arg>
					<arg n="1">step II</arg>
				</example>
				<example src="EGRAM" no="121">
					<text>slice site mutations that are able to specifically block step II does not affect the association of hPrps 16 and 17 with the sliceosome, indicating that these factors can work in a phase of step II before the recognition of the 3 slice site.</text>
					<arg n="0">slice site mutations</arg>
					<arg n="1">step II</arg>
				</example>
				<example src="EGRAM" no="121">
					<text>mutations of the cutting site that are able to specifically block step II does not affect the association of hPrps 16 and 17 with the sliceosome, indicating that these factors can work in a phase of step II before recognition of the 3-cut site.</text>
					<arg n="0">mutations of the cutting site</arg>
					<arg n="1">step II</arg>
				</example>
				<example src="EGRAM" no="122">
					<text>slice site mutations that are believed to specifically block step II does not affect the association of hPrps 16 and 17 with sclerosis, indicating that these factors can work in a step of step II before recognition of the 3 slice site.</text>
					<arg n="0">slice site mutations</arg>
					<arg n="1">step II</arg>
				</example>
				<example src="EGRAM" no="122">
					<text> Mutations at site 3 splice that are thought to specifically block step II do not affect the association of hPrps 16 and 17 with spliceosome, indicating that these factors can function at a stage of step II before the recognition of the site 3 splice.</text>
					<arg n="0"> Mutations at site 3 splice</arg>
					<arg n="1">step II</arg>
				</example>
				<example src="EGRAM" no="123">
					<text>mutations of the cutting site that are specifically shown to block step II does not affect the association of hPrps 16 and 17 with the sliceosome, indicating that these factors can work in a phase of step II before the recognition of the cutting site.</text>
					<arg n="0">mutations of the cutting site</arg>
					<arg n="1">step II</arg>
				</example>
				<example src="EGRAM" no="123">
					<text> Mutations in the 3 splice site that are specifically shown to block step II do not affect the association of hPrps 16 and 17 with the spliceosome, indicating that these factors can function at a stage of step II before the recognition of the 3 splice site.</text>
					<arg n="0"> Mutations in the 3 splice site</arg>
					<arg n="1">step II</arg>
				</example>
				<example src="EGRAM" no="124">
					<text>slice site mutations that can specifically block step II does not affect the association of hPrps 16 and 17 with the sliceosome, indicating that these factors can work in a phase of step II before the recognition of the 3 slice site.</text>
					<arg n="0">slice site mutations</arg>
					<arg n="1">step II</arg>
				</example>
				<example src="EGRAM" no="124">
					<text>mutations of the cutting site that can specifically block step II does not affect the association of hPrps 16 and 17 with the sliceosome, indicating that these factors can work in a phase of step II before recognition of the 3-cut site.</text>
					<arg n="0">mutations of the cutting site</arg>
					<arg n="1">step II</arg>
				</example>
				<example src="EGRAM" no="125">
					<text> Mutations in site 3 splice that have specifically blocked step II do not affect the association of hPrps 16 and 17 with spliceosome, indicating that these factors can function at a stage of step II before the recognition of the site 3 splice.</text>
					<arg n="0"> Mutations in site 3 splice</arg>
					<arg n="1">step II</arg>
				</example>
				<example src="EGRAM" no="125">
					<text>mutations of the cutting site that specifically blocked step II does not affect the association of hPrps 16 and 17 with the sliceosome, indicating that these factors can work in a phase of step II before the recognition of the cutting site.</text>
					<arg n="0">mutations of the cutting site</arg>
					<arg n="1">step II</arg>
				</example>
				<example src="EGRAM" no="126">
					<text>slice site mutations that can specifically block step II does not affect the association of hPrps 16 and 17 with the sliceosome, indicating that these factors can work in a phase of step II before the recognition of the 3 slice site.</text>
					<arg n="0">slice site mutations</arg>
					<arg n="1">step II</arg>
				</example>
				<example src="EGRAM" no="126">
					<text>mutations of the cutting site that can specifically block step II does not affect the association of hPrps 16 and 17 with the sliceosome, indicating that these factors can work in a phase of step II before recognition of the 3-cut site.</text>
					<arg n="0">mutations of the cutting site</arg>
					<arg n="1">step II</arg>
				</example>
				<example src="EGRAM" no="127">
					<text>slice site mutations that specifically blocked step II does not affect the association of hPrps 16 and 17 with the sliceosome, indicating that these factors can work in a phase of step II before the recognition of the slice site.</text>
					<arg n="0">slice site mutations</arg>
					<arg n="1">step II</arg>
				</example>
				<example src="EGRAM" no="127">
					<text>mutations of the cutting site that specifically blocked step II does not affect the association of hPrps 16 and 17 with the sliceosome, indicating that these factors can work in a phase of step II before the recognition of the cutting site.</text>
					<arg n="0">mutations of the cutting site</arg>
					<arg n="1">step II</arg>
				</example>
				<example src="EGRAM" no="128">
					<text>PU. 1 is altered early during the participation of multipotential progenitors for myeloid strains and inhibition of the PU.1 function on human progenitors CD34+ before this regulation blocks the formation of myeloid colonies.</text>
					<arg n="0">inhibition of the PU.1 function on human progenitors CD34+ before this regulation</arg>
					<arg n="1">formation of myeloid colonies</arg>
				</example>
				<example src="EGRAM" no="128">
					<text>PU.1 is blocks during the commitment of multi-potential progenitors to myeloid lineages and inhibition of the PU.1 function on human progenitors CD34+ before this regulation blocks formation of myeloid colonies.</text>
					<arg n="0">inhibition of the PU.1 function on human progenitors CD34+ before this regulation</arg>
					<arg n="1">formation of myeloid colonies</arg>
				</example>
				<example src="EGRAM" no="129">
					<text>PU. 1 is updated by early regulation during the involvement of multipotent progenitors with myeloid lines and inhibition of PU. 1 function in CD34+ human progenitors prior to this regulation may block myeloid colony formation.</text>
					<arg n="0">inhibition of PU. 1 function in CD34+ human progenitors prior to this regulation</arg>
					<arg n="1">myeloid colony formation</arg>
				</example>
				<example src="EGRAM" no="129">
					<text>PU.1 is updated by regulating early during the engagement of multi-potential progenitors with the myeloid lineages and inhibition of the PU.1 function on human progenitors CD34+ before this regulation can block formation of myeloid colonies.</text>
					<arg n="0">inhibition of the PU.1 function on human progenitors CD34+ before this regulation</arg>
					<arg n="1">formation of myeloid colonies</arg>
				</example>
				<example src="EGRAM" no="130">
					<text>UP. 1 is soon altered during the participation of multi-potential progenitors for myeloid strains and inhibition of UP.1 on human progenitors CD34+ before this regulation blocked formation of myeloid colonies.</text>
					<arg n="0">inhibition of UP.1 on human progenitors CD34+ before this regulation</arg>
					<arg n="1">formation of myeloid colonies</arg>
				</example>
				<example src="EGRAM" no="130">
					<text>PU.1 has been regulated very early during the commitment of multi-potential progenitors to myeloid lineages and inhibition of the PU.1 function on human progenitors CD34+ before this regulation has blocked formation of myeloid colonies.</text>
					<arg n="0">inhibition of the PU.1 function on human progenitors CD34+ before this regulation</arg>
					<arg n="1">formation of myeloid colonies</arg>
				</example>
				<example src="EGRAM" no="131">
					<text>PU.1 is updated during the engagement of multipotential progenitors with myeloid lineages and inhibition of the PU.1 function on human progenitors CD34+ before this regulation is able to block formation of myeloid colonies.</text>
					<arg n="0">inhibition of the PU.1 function on human progenitors CD34+ before this regulation</arg>
					<arg n="1">formation of myeloid colonies</arg>
				</example>
				<example src="EGRAM" no="131">
					<text>PU.1 is activated at the beginning of the multipotential progenitor abnormality for myeloid lineages and inhibition of the PU.1 function on human progenitors CD34+ before this regulation is able to block formation of myeloid colonies.</text>
					<arg n="0">inhibition of the PU.1 function on human progenitors CD34+ before this regulation</arg>
					<arg n="1">formation of myeloid colonies</arg>
				</example>
				<example src="EGRAM" no="132">
					<text>PU. 1 is updated to regulate early during the involvement of multipotential progenitors with myeloid and A0 strains (inhibition of PU. 1 function in CD34+ human progenitors prior to this Regulation) is considered to block myeloid colony formation.</text>
					<arg n="1">myeloid colony formation</arg>
				</example>
				<example src="EGRAM" no="132">
					<text>PU.1 is updated to regulate early during the engagement of multi-potential progenitors with the myeloid and A0 lineages (inhibition of the PU.1 function on human progenitors CD34+ before this regulation) is thought to block formation of myeloid colonies.</text>
					<arg n="1">formation of myeloid colonies</arg>
				</example>
				<example src="EGRAM" no="133">
					<text>PU. 1 is updated to regulate early during the involvement of multipotent progenitors with myeloid and A0 strains (inhibition of PU. 1 function in CD34+ human progenitors prior to this Regulation) is considered to have blocked myeloid colony formation.</text>
					<arg n="1">myeloid colony formation</arg>
				</example>
				<example src="EGRAM" no="133">
					<text>PU.1 is updated to regulate early during the engagement of multi-potential progenitors with the myeloid and A0 lineages (inhibition of the PU.1 function on human progenitors CD34+ before this regulation) is thought to have blocked formation of myeloid colonies.</text>
					<arg n="1">formation of myeloid colonies</arg>
				</example>
				<example src="EGRAM" no="134">
					<text>PU. 1 is updated by early regulation during the involvement of multipotent progenitors with myeloid lines and inhibition of PU. 1 function in CD34+ human progenitors prior to this Regulation has been shown to block myeloid colony formation.</text>
					<arg n="0">inhibition of PU. 1 function in CD34+ human progenitors prior to this Regulation</arg>
					<arg n="1">myeloid colony formation</arg>
				</example>
				<example src="EGRAM" no="134">
					<text>PU.1 is updated by regulating early during the engagement of multi-potential progenitors with the myeloid lineages and inhibition of the PU.1 function on human progenitors CD34+ before this regulation is shown to block formation of myeloid colonies.</text>
					<arg n="0">inhibition of the PU.1 function on human progenitors CD34+ before this regulation</arg>
					<arg n="1">formation of myeloid colonies</arg>
				</example>
				<example src="EGRAM" no="135">
					<text>UP. 1 is soon altered during the participation of multipotential progenitors for the myeloid and A0 lineages (up.1 inhibition of human progenitors CD34+ before this regulation) has been shown to blocked myeloid colony formation.</text>
					<arg n="1">myeloid colony formation</arg>
				</example>
				<example src="EGRAM" no="135">
					<text>PU.1 has been regulated very early during the commitment of multipotential progenitors to myeloid lineages and inhibition of the PU.1 function on human progenitors CD34+ before this regulation is shown to have blocked formation of myeloid colonies.</text>
					<arg n="0">inhibition of the PU.1 function on human progenitors CD34+ before this regulation</arg>
					<arg n="1">formation of myeloid colonies</arg>
				</example>
				<example src="EGRAM" no="136">
					<text>PU. 1 is altered early during the participation of multipotential progenitors for myeloid strains and inhibition of the PU.1 function on human progenitors CD34+ before this regulation will block formation of myeloid colonies.</text>
					<arg n="0">inhibition of the PU.1 function on human progenitors CD34+ before this regulation</arg>
					<arg n="1">formation of myeloid colonies</arg>
				</example>
				<example src="EGRAM" no="136">
					<text>PU.1 is updated by regulation early during the engagement of multi-potential progenitors with the myeloid lineages and inhibition of the PU.1 function in humans CD34+ before this regulation will block formation of myeloid colonies.</text>
					<arg n="0">inhibition of the PU.1 function in humans CD34+ before this regulation</arg>
					<arg n="1">formation of myeloid colonies</arg>
				</example>
				<example src="EGRAM" no="137">
					<text>UP. 1 is soon altered during the participation of multipotential progenitors for the myeloid lineages and formation of myeloid colonies can be blocked by inhibition of UP.1 on the CD34+ human progenitors before this regulation.</text>
					<arg n="0">inhibition of UP.1 on the CD34+ human progenitors before this regulation</arg>
					<arg n="1">formation of myeloid colonies</arg>
				</example>
				<example src="EGRAM" no="137">
					<text>PU.1 is updated by regulation early during the engagement of multi-potential progenitors with the myeloid lineages and formation of myeloid colonies can be blocked by inhibition of the PU.1 function on the CD34+ human progenitors before this regulation.</text>
					<arg n="0">inhibition of the PU.1 function on the CD34+ human progenitors before this regulation</arg>
					<arg n="1">formation of myeloid colonies</arg>
				</example>
				<example src="EGRAM" no="138">
					<text>UP. 1 is activated early during the multi-potential negotiation of progenitors for myeloid lineages and formation of myeloid colonies is thought to be blocked by inhibition of UP.1 functions on CD34+ human progenitors before this regulation.</text>
					<arg n="0">inhibition of UP.1 functions on CD34+ human progenitors before this regulation</arg>
					<arg n="1">formation of myeloid colonies</arg>
				</example>
				<example src="EGRAM" no="138">
					<text>PU.1 is updated by regulating early during the engagement of multi-potential progenitors with the myeloid and A1 lineages (formation of myeloid colonies) is thought to be blocked by inhibition of the PU.1 function on the CD34+ human progenitors before this regulation.</text>
					<arg n="0">inhibition of the PU.1 function on the CD34+ human progenitors before this regulation</arg>
				</example>
				<example src="EGRAM" no="139">
					<text>PU.1 is updated during multi-potential parent engagement with myeloid lineages and Meloid colony formation is blocked by inhibition of the PU.1 function on CD34+ human progenitors before this regulation.</text>
					<arg n="0">inhibition of the PU.1 function on CD34+ human progenitors before this regulation</arg>
					<arg n="1">Meloid colony formation</arg>
				</example>
				<example src="EGRAM" no="139">
					<text>UP. 1 is soon altered during the participation of multipotential progenitors by myeloid lineages and formation of myeloid colonies is blocked by inhibition of UP.1 functions on CD34+ human progenitors before this regulation.</text>
					<arg n="0">inhibition of UP.1 functions on CD34+ human progenitors before this regulation</arg>
					<arg n="1">formation of myeloid colonies</arg>
				</example>
				<example src="EGRAM" no="140">
					<text>PU.1 is updated during multi-potential parent engagement with the myeloid and A1 lineages (formation of myeloid colonies) can be blocked by inhibition of the PU.1 function on the CD34+ human progenitors before this regulation.</text>
					<arg n="0">inhibition of the PU.1 function on the CD34+ human progenitors before this regulation</arg>
				</example>
				<example src="EGRAM" no="140">
					<text>UP. 1 is early altered during the involvement of multipotential progenitors for myeloid lineages and myeloid colony formation may be blocked by A0 (inhibition of UP. 1 function in human CD34+ progenitors prior to this regulation.</text>
					<arg n="1">myeloid colony formation</arg>
				</example>
				<example src="EGRAM" no="141">
					<text>UP. 1 is activated at the start of the multipotential parent commitment for myeloid and A1 lineages (the formation of myeloid colonies) will be blocked by inhibition of UP functions on the CD34+ human progenitors before this regulation.</text>
					<arg n="0">inhibition of UP functions on the CD34+ human progenitors before this regulation</arg>
				</example>
				<example src="EGRAM" no="141">
					<text>PU.1 is updated early during the engagement of multi-potential progenitors with the myeloid lineages and formation of myeloid colonies will be blocked by inhibition of the PU.1 function on human progenitors CD34+ before this regulation.</text>
					<arg n="0">inhibition of the PU.1 function on human progenitors CD34+ before this regulation</arg>
					<arg n="1">formation of myeloid colonies</arg>
				</example>
				<example src="EGRAM" no="142">
					<text>PU.1 was regulated at the start of multipotential progenitor commitment for myeloid strains and inhibition of PU.1 function in CD34+ human progenitors prior to this Regulation blocked myeloid colony formation.</text>
					<arg n="0">inhibition of PU.1 function in CD34+ human progenitors prior to this Regulation</arg>
					<arg n="1">myeloid colony formation</arg>
				</example>
				<example src="EGRAM" no="142">
					<text>PU.1 was regulated at the beginning of the commitment of multi-potential progenitors to myeloid lineages and inhibition of the PU.1 function on human progenitors CD34+ before this regulation blocked formation of myeloid colonies.</text>
					<arg n="0">inhibition of the PU.1 function on human progenitors CD34+ before this regulation</arg>
					<arg n="1">formation of myeloid colonies</arg>
				</example>
				<example src="EGRAM" no="143">
					<text>PU.1 was regulated at the start of multipotential progenitor commitment for myeloid strains and inhibition of PU.1 function in CD34+ human progenitors prior to this Regulation blocked myeloid colony formation.</text>
					<arg n="0">inhibition of PU.1 function in CD34+ human progenitors prior to this Regulation</arg>
					<arg n="1">myeloid colony formation</arg>
				</example>
				<example src="EGRAM" no="143">
					<text>PU.1 was regulated at the beginning of the commitment of multi-potential progenitors to myeloid lineages and inhibition of the PU.1 function on human progenitors CD34+ before this regulation has blocked formation of myeloid colonies.</text>
					<arg n="0">inhibition of the PU.1 function on human progenitors CD34+ before this regulation</arg>
					<arg n="1">formation of myeloid colonies</arg>
				</example>
				<example src="EGRAM" no="144">
					<text>UP. 1 was previously regulated during the participation of multi-potential progenitors for myeloid strains and formation of myeloid colonies was blocked by A0 (inhibition of UP.1 functions on human progenitors CD34+ before this regulation.</text>
					<arg n="1">formation of myeloid colonies</arg>
				</example>
				<example src="EGRAM" no="144">
					<text>PU.1 was regulated at the beginning of the commitment of multi-potential progenitors to the myeloid lineages and formation of myeloid colonies has been blocked by inhibition of the PU.1 function on the CD34+ human progenitors before this regulation.</text>
					<arg n="0">inhibition of the PU.1 function on the CD34+ human progenitors before this regulation</arg>
					<arg n="1">formation of myeloid colonies</arg>
				</example>
				<example src="EGRAM" no="145">
					<text>PU.1 was regulated at the beginning of multipotential progenitor commitment for myeloid strains and myeloid colony formation was blocked by inhibition of PU.1 function in CD34+ human progenitors prior to this regulation.</text>
					<arg n="0">inhibition of PU.1 function in CD34+ human progenitors prior to this regulation</arg>
					<arg n="1">myeloid colony formation</arg>
				</example>
				<example src="EGRAM" no="145">
					<text>PU.1 was regulated at the beginning of the commitment of multi-potential progenitors to the myeloid lineages and formation of myeloid colonies was blocked by inhibition of the PU.1 function on human progenitors CD34+ before this regulation.</text>
					<arg n="0">inhibition of the PU.1 function on human progenitors CD34+ before this regulation</arg>
					<arg n="1">formation of myeloid colonies</arg>
				</example>
				<example src="EGRAM" no="146">
					<text>Proeasomal inhibition cannot induce any synergic effect on the increase of GR 14-3-3eta induced in response to glucocorticoid, and translation inhibition cannot block relevation of GR by 14-3-3eta, indicating that 14-3-3eta induces GR stabilization.</text>
					<arg n="0">translation inhibition</arg>
					<arg n="1">relevation of GR by 14-3-3eta</arg>
				</example>
				<example src="EGRAM" no="146">
					<text>Proassmal inhibition cannot induce any synergistic effect on the increase of GR 14-3-3eta induced in response to glucocorticoid, and translation inhibition cannot block relevance of GR by 14-3-3eta, indicating that 14-3-3eta induces GR stabilization.</text>
					<arg n="0">translation inhibition</arg>
					<arg n="1">relevance of GR by 14-3-3eta</arg>
				</example>
				<example src="EGRAM" no="147">
					<text>Proteasomal inhibition cannot induce any synergistic effect on the increase of GR induced by 14-3-3eta in response to glucocorticoids, and translation inhibition is not able to block GR elevation in 14-3-3eta, indicating that 14-3-3eta induces GR stabilization.</text>
					<arg n="0">translation inhibition</arg>
					<arg n="1">GR elevation in 14-3-3eta</arg>
				</example>
				<example src="EGRAM" no="147">
					<text>Proeasomal inhibition cannot induce any synergic effect on the increase of GR 14-3-3eta in response to glucocorticoid, and translation inhibition is not able to block rain of GR by 14-3-3eta, indicating that 14-3-3eta induces GR stabilization.</text>
					<arg n="0">translation inhibition</arg>
					<arg n="1">rain of GR by 14-3-3eta</arg>
				</example>
				<example src="EGRAM" no="148">
					<text>Proeasomal inhibition does not induce any synergic effect on the increase of GR 14-3-3eta in response to glucocorticoid, and rain of GR by 14-3-3eta cannot be blocked by translation inhibition, indicating that 14-3-3eta induces GR stabilization.</text>
					<arg n="0">translation inhibition</arg>
					<arg n="1">rain of GR by 14-3-3eta</arg>
				</example>
				<example src="EGRAM" no="148">
					<text>Proeasomal inhibition does not induce any synergic effect on the increase of GR induced by 14-3-3eta in response to glucocorticoids, and increasing GR by 14-3-3eta cannot be blocked by inhibition of translation, indicating that 14-3-3eta induces GR stabilization.</text>
					<arg n="0">inhibition of translation</arg>
					<arg n="1">increasing GR by 14-3-3eta</arg>
				</example>
				<example src="EGRAM" no="149">
					<text>Proeasomal inhibition does not induce any synergic effect on the increase of GR 14-3-3eta in response to glucocorticoid, and it is believed that rain of GR by 14-3-3eta is not blocked by translation inhibition, indicating that 14-3-3eta induces GR stabilization.</text>
					<arg n="0">translation inhibition</arg>
					<arg n="1">rain of GR by 14-3-3eta</arg>
				</example>
				<example src="EGRAM" no="149">
					<text>Proeasomal inhibition does not induce any synergic effect on the increase of GR induced by 14-3-3eta in response to glucocorticoids, and it is believed that greater GR in 14-3-3eta is not blocked by inhibition of translation, indicating that 14-3-3eta induces GR stabilization.</text>
					<arg n="0">inhibition of translation</arg>
					<arg n="1">greater GR in 14-3-3eta</arg>
				</example>
				<example src="EGRAM" no="150">
					<text>Proeasomal inhibition does not induce any synergic effect on the increase of GR induced by 14-3-3eta in response to glucocorticoids, and the elevation of GR in 14-3-3eta is not capable of being blocked by translation inhibition, indicating that 14-3-3eta induces GR stabilization.</text>
					<arg n="0">translation inhibition</arg>
					<arg n="1">the elevation of GR in 14-3-3eta</arg>
				</example>
				<example src="EGRAM" no="150">
					<text>Proteasomal inhibition does not induce any synergistic effect on the increase of GR induced by 14-3-3eta in response to glucocorticoids, and GR elevation in 14-3-3eta is not able to be blocked by translation inhibition, indicating that 14-3-3eta induces GR stabilization.</text>
					<arg n="0">translation inhibition</arg>
					<arg n="1">GR elevation in 14-3-3eta</arg>
				</example>
				<example src="EGRAM" no="151">
					<text>Proeasomal inhibition does not induce any synergic effect on the increase of GR 14-3-3eta in response to glucocorticoid, and rain of GR by 14-3-3eta is not blocked by translation inhibition, indicating that 14-3-3eta induces GR stabilization.</text>
					<arg n="0">translation inhibition</arg>
					<arg n="1">rain of GR by 14-3-3eta</arg>
				</example>
				<example src="EGRAM" no="151">
					<text>Proeasomal inhibition does not induce any synergic effect on the increase of GR induced by 14-3-3eta in response to glucocorticoids, and greater GR in 14-3-3eta is not blocked by inhibition of translation, indicating that 14-3-3eta induces GR stabilization.</text>
					<arg n="0">inhibition of translation</arg>
					<arg n="1">greater GR in 14-3-3eta</arg>
				</example>
				<example src="EGRAM" no="152">
					<text>Proteasomal inhibition does not induce any synergistic effect on the increase of GR induced by 14-3-3eta in response to glucocorticoids, and translation inhibition does not block GR elevation in 14-3-3eta, indicating that 14-3-3eta induces GR stabilization.</text>
					<arg n="0">translation inhibition</arg>
					<arg n="1">GR elevation in 14-3-3eta</arg>
				</example>
				<example src="EGRAM" no="152">
					<text>Proeasomal inhibition does not induce any synergic effect on the increase of GR 14-3-3eta in response to glucocorticoid, and translation inhibition does not block rain of GR by 14-3-3eta, indicating that 14-3-3eta induces GR stabilization.</text>
					<arg n="0">translation inhibition</arg>
					<arg n="1">rain of GR by 14-3-3eta</arg>
				</example>
				<example src="EGRAM" no="153">
					<text>Proteasomal inhibition did not induce any synergistic effect on the increase of GR induced by 14-3-3eta in response to glucocorticoids, and translation inhibition did not blocked GR elevation in 14-3-3eta, indicating that 14-3-3eta induced GR stabilization.</text>
					<arg n="0">translation inhibition</arg>
					<arg n="1">GR elevation in 14-3-3eta</arg>
				</example>
				<example src="EGRAM" no="153">
					<text>Proeasomal inhibition has not induced any synergic effect on the increase of GR 14-3-3eta in response to glucocorticoid, and translation inhibition has not blocked rain of GR by 14-3-3eta, indicating that 14-3-3eta induces GR stabilization.</text>
					<arg n="0">translation inhibition</arg>
					<arg n="1">rain of GR by 14-3-3eta</arg>
				</example>
				<example src="EGRAM" no="154">
					<text>Proassmal inhibition does not induce any synergistic effect on the increase of GR 14-3-3eta in response to glucocorticoids, and translation inhibition does not block release of GR by 14-3-3eta, indicating that 14-3-3eta induces GR stabilization.</text>
					<arg n="0">translation inhibition</arg>
					<arg n="1">release of GR by 14-3-3eta</arg>
				</example>
				<example src="EGRAM" no="154">
					<text>Proeasomal inhibition will not induce any synergic effect on the increase of GR 14-3-3eta in response to glucocorticoid, and translation inhibition will not block relevation of GR by 14-3-3eta, indicating that 14-3-3eta induces GR stabilization.</text>
					<arg n="0">translation inhibition</arg>
					<arg n="1">relevation of GR by 14-3-3eta</arg>
				</example>
				<example src="EGRAM" no="155">
					<text>Step II can be specifically blocked by  3-slice site mutations that do not affect the association of hPrps 16 and 17 with the sliceosome, indicating that these factors can work in a phase of of 2 before the recognition of the 3-slice site.</text>
					<arg n="0"> 3-slice site mutations</arg>
					<arg n="1">of 2</arg>
				</example>
				<example src="EGRAM" no="155">
					<text>Step II can be specifically blocked for  Mutations in cut-off site 3 that do not affect the association of hPrps 16 and 17 with spliceosome, indicating that these factors can operate in a stage of step II before the recognition of the splice 3 site.</text>
					<arg n="0"> Mutations in cut-off site 3</arg>
					<arg n="1">step II</arg>
				</example>
				<example src="EGRAM" no="156">
					<text>It is believed that Step II is specifically blocked to sectional site mutations that do not affect the association of hPrps 16 and 17 with splenosome, indicating that these factors may work in the A1 stage (section 2) before recognition of the sectional site.</text>
					<arg n="0">sectional site mutations</arg>
				</example>
				<example src="EGRAM" no="156">
					<text>Step II is believed to be specifically blocked for  Mutations at the site of 3 cuts that do not affect the association of hPrps 16 and 17 with the spliceosome, indicating that these factors can function at a stage of step II before recognition of the site of 3 cuts.</text>
					<arg n="0"> Mutations at the site of 3 cuts</arg>
					<arg n="1">step II</arg>
				</example>
				<example src="EGRAM" no="157">
					<text>Step II is specifically blocked by mutations to the 3rd place of the ear that do not affect the association of hPrps 16 and 17 with the ear, indicating that these factors can operate in a phase of of step II before the recognition of site 3.</text>
					<arg n="0">mutations to the 3rd place of the ear</arg>
					<arg n="1">of step II</arg>
				</example>
				<example src="EGRAM" no="157">
					<text>Step II is specifically blocked for  Mutations at the site of 3 cuts that do not affect the association of hPrps 16 and 17 with the spliceosome, indicating that these factors can function at a stage of step II before recognition of the site of 3 cuts.</text>
					<arg n="0"> Mutations at the site of 3 cuts</arg>
					<arg n="1">step II</arg>
				</example>
				<example src="EGRAM" no="158">
					<text>Step II was specifically blocked for mutations to the site of the 3rd portion that do not affect the association of hPrps 16 and 17 to the sliceosome, indicating that these factors can work in a phase of step II before the recognition of the site of the 3rd portion.</text>
					<arg n="0">mutations to the site of the 3rd portion</arg>
					<arg n="1">step II</arg>
				</example>
				<example src="EGRAM" no="158">
					<text>Step II was specifically blocked by mutations at the 3rd splice site which do not affect the association of hPrps 16 and 17 to the sliceosome, indicating that these factors can work in a phase of step II before the recognition of the 3rd splice site.</text>
					<arg n="0">mutations at the 3rd splice site</arg>
					<arg n="1">step II</arg>
				</example>
				<example src="EGRAM" no="159">
					<text>Tagetin is more specific for the distinction between different RNA polymerases, since RNA polymerase during stretching can be blocked by it (Mathews and Durbin, 1994), i.e., its action is independent of different initial factors.</text>
					<arg n="0">Tagetin</arg>
					<arg n="1">RNA polymerase during stretching</arg>
				</example>
				<example src="EGRAM" no="159">
					<text>Tagetin is more specific to distinguish between different RNA polymerases because RNA polymerase during elongation can be blocked by it (Mathews and Durbin, 1994), i.e., the action is independent of different initiation factors.</text>
					<arg n="0">Tagetin</arg>
					<arg n="1">RNA polymerase during elongation</arg>
				</example>
				<example src="EGRAM" no="160">
					<text>Tagetin is more specific to distinguish between different RNA polymerases because RNA polymerase during elongation can be blocked by it (Mathews and Durbin, 1994), i.e., the action is independent of different initiation factors.</text>
					<arg n="0">Tagetin</arg>
					<arg n="1">RNA polymerase during elongation</arg>
				</example>
				<example src="EGRAM" no="160">
					<text>Tagetin is more specific for the distinction between different RNA polymerases, since RNA polymerase during stretching is able to be blocked by it (Mathews and Durbin, 1994), i.e., its action is independent of different initial factors.</text>
					<arg n="0">Tagetin</arg>
					<arg n="1">RNA polymerase during stretching</arg>
				</example>
				<example src="EGRAM" no="161">
					<text>Tagetin is more specific for the distinction between different RNA polymerases, since RNA polymerase during stretching is blocked by it (Mathews and Durbin, 1994), i.e., its action is independent of different initial factors.</text>
					<arg n="0">Tagetin</arg>
					<arg n="1">RNA polymerase during stretching</arg>
				</example>
				<example src="EGRAM" no="161">
					<text>Tagetin is more specific to distinguish between different RNA polymerases because RNA polymerase during elongation is blocked by it (Mathews and Durbin, 1994), i.e., the action is independent of different initiation factors.</text>
					<arg n="0">Tagetin</arg>
					<arg n="1">RNA polymerase during elongation</arg>
				</example>
				<example src="EGRAM" no="162">
					<text>Tagetin is more specific for the distinction between different RNA polymerases, since RNA polymerase during stretching was blocked by it (Mathews and Durbin, 1994), i.e., its action is independent of different initial factors.</text>
					<arg n="0">Tagetin</arg>
					<arg n="1">RNA polymerase during stretching</arg>
				</example>
				<example src="EGRAM" no="162">
					<text>Tagetin is more specific to distinguish between different RNA polymerases because RNA polymerase during elongation was blocked by it (Mathews and Durbin, 1994), i.e., the action is independent of different initiation factors.</text>
					<arg n="0">Tagetin</arg>
					<arg n="1">RNA polymerase during elongation</arg>
				</example>
				<example src="EGRAM" no="163">
					<text>Tagetin is more specific for the distinction between different RNA polymerases, because it blocked RNA polymerase during stretching (Mathews and Durbin, 1994), i.e., its action is independent of different initial factors.</text>
					<arg n="0">Tagetin</arg>
					<arg n="1">RNA polymerase during stretching</arg>
				</example>
				<example src="EGRAM" no="163">
					<text>Tagetin is more specific for the distinction between different RNA polymerases, because it blocked RNA polymerase during stretching (Mathews and Durbin, 1994), i.e., the action is independent of different initial factors.</text>
					<arg n="0">Tagetin</arg>
					<arg n="1">RNA polymerase during stretching</arg>
				</example>
				<example src="EGRAM" no="164">
					<text>Tagetin is more specific for the distinction between different RNA polymerases, as it can block RNA polymerase during stretching (Mathews and Durbin, 1994), i.e., its action is independent of different initial factors.</text>
					<arg n="0">Tagetin</arg>
					<arg n="1">RNA polymerase during stretching</arg>
				</example>
				<example src="EGRAM" no="164">
					<text>Tagetin is more specific to distinguish between different RNA polymerases because it can block RNA polymerase during elongation (Mathews and Durbin, 1994), i.e., the action is independent of different initiation factors.</text>
					<arg n="0">Tagetin</arg>
					<arg n="1">RNA polymerase during elongation</arg>
				</example>
				<example src="EGRAM" no="165">
					<text>Tagetin is more specific to distinguish between different RNA polymerases because it is able to block RNA polymerase during elongation (Mathews and Durbin, 1994), i.e., the action is independent of different initiation factors.</text>
					<arg n="0">Tagetin</arg>
					<arg n="1">RNA polymerase during elongation</arg>
				</example>
				<example src="EGRAM" no="165">
					<text>A0 is more specific for the distinction between different RNA polymerases, as it is able to block RNA polymerase during stretch (Mathews and Durbin, 1994), i.e., its action is independent of different initiation factors.</text>
					<arg n="1">RNA polymerase during stretch</arg>
				</example>
				<example src="EGRAM" no="166">
					<text>Tagetin is more specific for the distinction between different RNA polymerases, as it can blocks RNA polymerase during stretching (Mathews and Durbin, 1994), i.e., its action is independent of different initial factors.</text>
					<arg n="0">Tagetin</arg>
					<arg n="1">RNA polymerase during stretching</arg>
				</example>
				<example src="EGRAM" no="166">
					<text>Tagetin is more specific to distinguish between different RNA polymerases because it can blocks RNA polymerase during elongation (Mathews and Durbin, 1994), i.e., the action is independent of different initiation factors.</text>
					<arg n="0">Tagetin</arg>
					<arg n="1">RNA polymerase during elongation</arg>
				</example>
				<example src="EGRAM" no="167">
					<text>These results suggest that 14-3eta functions as positive regulation in the signaling pathway of glucocorticoids by blocking GR degradation and induction of GR elevation, thus increasing the transcriptional activity of GR.</text>
					<arg n="0">positive regulation in the signaling pathway of glucocorticoids</arg>
					<arg n="1">GR degradation and induction of GR elevation</arg>
				</example>
				<example src="EGRAM" no="167">
					<text>These results suggest that 14-3-3eta functions as a positive regulator in the glucocorticoid signal pathway by blocking the degradation of GR and induced a GR elevation, thus improving the transcriptional activity of GR.</text>
					<arg n="0">a positive regulator in the glucocorticoid signal pathway</arg>
					<arg n="1">the degradation of GR and induced a GR elevation</arg>
				</example>
				<example src="EGRAM" no="168">
					<text>These results suggest that 14-3eta functions as positive regulation in the signaling pathway of glucocorticoids by blocking GR degradation and induction of GR elevation, thus increasing the transcriptional activity of GR.</text>
					<arg n="0">positive regulation in the signaling pathway of glucocorticoids</arg>
					<arg n="1">GR degradation and induction of GR elevation</arg>
				</example>
				<example src="EGRAM" no="168">
					<text>These results suggest that 14-3eta functions as a positive regulator in the glucocorticoid signal pathway by blocking the degradation of GR and induced a GR elevation, thus improving the transcriptional activity of GR.</text>
					<arg n="0">a positive regulator in the glucocorticoid signal pathway</arg>
					<arg n="1">the degradation of GR and induced a GR elevation</arg>
				</example>
				<example src="EGRAM" no="169">
					<text>These results suggest that 14-3eta functions as positive regulation in the signaling pathway of glucocorticoids to blocking GR degradation and induction of GR elevation, thus increasing the transcriptional activity of GR.</text>
					<arg n="0">positive regulation in the signaling pathway of glucocorticoids</arg>
					<arg n="1">GR degradation and induction of GR elevation</arg>
				</example>
				<example src="EGRAM" no="169">
					<text>These results suggest that 14-3-3eta functions as a positive regulator in the glucocorticoid signal pathway to blocking the degradation of GR and induce a GR elevation, thus improving the transcriptional activity of GR.</text>
					<arg n="0">a positive regulator in the glucocorticoid signal pathway</arg>
					<arg n="1">the degradation of GR and induce a GR elevation</arg>
				</example>
				<example src="EGRAM" no="170">
					<text>These results suggest that 14-3eta functions as positive regulation in the signaling pathway of glucocorticoids which blocked degradation of GR and induction of GR elevation, thus increasing the transcriptional activity of GR.</text>
					<arg n="0">positive regulation in the signaling pathway of glucocorticoids</arg>
					<arg n="1">degradation of GR and induction of GR elevation</arg>
				</example>
				<example src="EGRAM" no="170">
					<text>These results suggest that 14-3eta functions as a positive regulator in the glucocorticoid signal pathway that blocked the degradation of GR and induces a GR elevation, thus improving the transcriptional activity of GR.</text>
					<arg n="0">a positive regulator in the glucocorticoid signal pathway</arg>
					<arg n="1">the degradation of GR and induces a GR elevation</arg>
				</example>
				<example src="EGRAM" no="171">
					<text>These results suggest that 14-3eta functions as positive regulation in the signaling pathway of glucocorticoids that block degradation of GR and induce elevation of GR, thus blocked the transcriptional activity of GR.</text>
					<arg n="0">positive regulation in the signaling pathway of glucocorticoids</arg>
					<arg n="1">degradation of GR and induce elevation of GR</arg>
				</example>
				<example src="EGRAM" no="171">
					<text>These results suggest that 14-3eta functions as a positive regulator in the glucocorticoid signal pathway that has blocked the degradation of GR and the induction of a GR lift, thus improving the transcriptional activity of GR.</text>
					<arg n="0">a positive regulator in the glucocorticoid signal pathway</arg>
					<arg n="1">the degradation of GR and the induction of a GR lift</arg>
				</example>
				<example src="EGRAM" no="172">
					<text>the action of a postulated repressor can be blocked by alanine.</text>
					<arg n="0">alanine</arg>
					<arg n="1">the action of a postulated repressor</arg>
				</example>
				<example src="EGRAM" no="172">
					<text>the action of a postulate repressor can be blocked by alanine.</text>
					<arg n="0">alanine</arg>
					<arg n="1">the action of a postulate repressor</arg>
				</example>
				<example src="EGRAM" no="173">
					<text>the action of a prescribed repressor was blocked by alanine.</text>
					<arg n="0">alanine</arg>
					<arg n="1">the action of a prescribed repressor</arg>
				</example>
				<example src="EGRAM" no="173">
					<text>the action of a postulate repressor has been blocked by Alanine.</text>
					<arg n="0">Alanine</arg>
					<arg n="1">the action of a postulate repressor</arg>
				</example>
				<example src="EGRAM" no="174">
					<text>the action of a prescribed repressor is blocked by alanine.</text>
					<arg n="0">alanine</arg>
					<arg n="1">the action of a prescribed repressor</arg>
				</example>
				<example src="EGRAM" no="174">
					<text>the action of a postulate repressor is blocked by Alanine.</text>
					<arg n="0">Alanine</arg>
					<arg n="1">the action of a postulate repressor</arg>
				</example>
				<example src="EGRAM" no="175">
					<text>action of a prescribed repressor was blocked by alanine.</text>
					<arg n="0">alanine</arg>
					<arg n="1">action of a prescribed repressor</arg>
				</example>
				<example src="EGRAM" no="175">
					<text>the action of a postulate repressor was blocked by Alanine.</text>
					<arg n="0">Alanine</arg>
					<arg n="1">the action of a postulate repressor</arg>
				</example>
			</roleset>
        </predicate>
    </framesest>
</PASBIO>